



Emerging roles of mitochondrial functions and epigenetic changes in the modulation of stem cell fate

Chensong Zhang¹ · Yang Meng¹ · Junhong Han¹

Received: 1 November 2023 / Revised: 27 November 2023 / Accepted: 28 November 2023
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024

Abstract

Mitochondria serve as essential organelles that play a key role in regulating stem cell fate. Mitochondrial dysfunction and stem cell exhaustion are two of the nine distinct hallmarks of aging. Emerging research suggests that epigenetic modification of mitochondria-encoded genes and the regulation of epigenetics by mitochondrial metabolites have an impact on stem cell aging or differentiation. Here, we review how key mitochondrial metabolites and behaviors regulate stem cell fate through an epigenetic approach. Gaining insight into how mitochondria regulate stem cell fate will help us manufacture and preserve clinical-grade stem cells under strict quality control standards, contributing to the development of aging-associated organ dysfunction and disease.

Keywords Mitochondria · Stem cell fate · Epigenetic modifications · Mitochondria metabolites · Senescence

Introduction

It is now clear that epigenetic changes are one of the primary causes of aging in mammals, and restoring epigenome integrity can reverse signs of aging [1]. Epigenetic regulation of mitochondrial DNA (mtDNA) is an emerging and rapidly growing field of research. The generation and modification of epigenetic marks in the nucleus require metabolites provided by the mitochondria, and subsequently, these epigenetic marks modulate the expression of proteins within the mitochondria [2]. It is currently believed that mitochondrial epigenetics is regulated in four main ways: (1) epigenetic mechanisms that regulate nuclear-encoded mitochondrial

genes affect mitochondria; (2) cell-specific mtDNA content and mitochondrial activity determine the level of methylation of nuclear genes; (3) mtDNA variation affects the pattern of nuclear gene expression and the degree of methylation of nuclear DNA; and (4) mtDNA itself is subjected to epigenetic modifications [3, 4]. In recent years, numerous studies have validated the crucial function of mitochondria in controlling the destiny of stem cells [5–7]. An increasing number of studies are concentrating on the epigenetic mechanisms by which mitochondria sustain stem cell proliferation, renewal, differentiation, and lifespan.

The impact of epigenetic dysregulation on adult stem cell function varies widely, ranging from nonsignificant to significant, depending on the tissue type and the specific epigenetic regulator affected [8]. Self-renewal and pluripotency are two key properties of stem cells [9]. Stem cell therapy is currently one of the most popular fields in regenerative medicine [10]. The basic idea is to plant selected stem cells into the patient's body through specific methods to promote regeneration of pathological tissues for therapeutic purposes [11]. Precise regulation of these two properties is the basis for ensuring healthy cell development and tissue homeostasis in stem cell therapy. The network of transcription factors regulating stem cell stemness and differentiation has been thoroughly studied [12–14]. Other aspects of regulation, such as miRNAs and epigenetic modification, have also been extensively studied [15–19]. Although posttranslational

Chensong Zhang and Yang Meng have contributed equally to this work.

✉ Junhong Han
hjunhong@scu.edu.cn

Chensong Zhang
chensongzhang@stu.scu.edu.cn

Yang Meng
myang@wchscu.edu.cn

¹ State Key Laboratory of Biotherapy and Cancer Center, Frontiers Science Center for Disease-Related Molecular Network, and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China

regulatory mechanisms have been poorly studied, recent studies have shown that protein quality control (PQC) is closely related to stem cell function [20–23].

Here, we focus on the influence of mitochondria and their metabolites on the fate of stem cells. In this review, we overview how the metabolites of the tricarboxylic acid cycle (TCA) in mitochondria support the survival and growth of stem cells. Additionally, we highlight the signaling function of mitochondria, which alters epigenetic remodeling through the mitochondrial stress response and mitochondrial dynamics during cell fate determination.

Mitochondrial metabolites are the material basis of epigenetic influence on stem cell senescence

Mitochondrial metabolites are important components of epigenetic pathways. It is increasingly recognized that metabolic signals originating from mitochondria initiate epigenetic modifications in the nucleus through nonmetabolic mechanisms [24]. Recent studies have found that mitochondrial metabolites regulate the epigenetic landscape that determines cell identity and function [25]. In particular, there is evidence to suggest that mitochondrial metabolites are involved in the regulation of epigenetic modifications, including chromatin structure regulation, DNA methylation, histone modification and noncoding RNA regulation. Moreover, it has been demonstrated that mitochondrial metabolism plays important roles in modulating gene transcription, DNA damage levels, and long-term developmental pathways in stem cells [26, 27]. Therefore, mitochondrial metabolites offer essential regulation of stem cell fate when properly harnessed. Overall, these studies underscore the significance of mitochondrial metabolites in governing the progression and sustenance of stem cells while also highlighting their prospective applications in regenerative medicine.

Stem cell identity and function are largely determined by gene expression profiles. In eukaryotic cells, gene transcription is regulated by the interaction between transcription factors and chromatin remodeling and modification factors [28]. The methylation of DNA and histones generally promotes the self-renewal of adult stem cells, while demethylation leads to stem cell activation, proliferation, and differentiation [29]. Furthermore, different metabolites of the TCA cycle are utilized as substrates by chromatin-modifying enzymes, which control gene expression by altering chromatin modification [30]. Acetyl-coenzyme A (acetyl-CoA) and alpha-ketoglutarate (α -KG) have been extensively studied for their

role in modulating the fate of mammalian embryonic stem cells and adult stem cells [6, 31].

In this section, we will discuss several mitochondrial metabolites, including acetyl-CoA, α -KG, nicotinamide adenine dinucleotide (NAD⁺), and S-adenosylmethionine (SAM), as potential cell regulatory factors and how changes in their abundance influence the epigenomes and the aging process in different organisms (Fig. 1).

Acetyl-CoA

Acetyl-CoA, which is necessary for histone acetylation, is produced in the cytoplasm by ATP citrate lyase (ACLY) and ACSS2, a member of the acyl-CoA synthetase short-chain family, using citrate and acetate as substrates, respectively [28]. Under conditions of nutrient restriction, ACSS2, a cytosolic enzyme belonging to the short-chain family of acyl-CoA synthetases 2, plays a crucial role in generating acetyl-CoA by utilizing acetate as a substrate [32, 33]. Subsequently, acetyl-CoA is utilized in the mitochondria to generate citric acid and oxaloacetic acid via the TCA cycle [24]. In addition to its roles in metabolism and biosynthesis, acetyl-CoA provides acetyl groups for protein acetylation, such as histone acetylation, which is catalyzed by histone acetyltransferases (HATS) [34]. Acetylation neutralizes the positive charge on lysine residues, resulting in the opening of chromatin structures, which allows for the entry of transcription factors and impacts gene expression [34]. Therefore, acetyl coactivators serve as substrates for acetylation and regulate the nuclear epigenome of stem cells.

Hematopoietic stem cells (HSCs) primarily rely on anaerobic glycolysis to generate energy and remain stationary and undifferentiated, while their mitochondria remain active. As glycolysis and the TCA cycle are not directly linked in HSCs, they use other nutritional pathways, such as amino acid and fatty acid metabolism, to produce acetyl-CoA to fuel the TCA cycle. Recent studies have further revealed a connection between acetyl-CoA metabolism and histone acetylation in HSCs during hematopoietic recovery after bone marrow ablation [35].

Mouse and human pluripotent stem cells (PSCs) possess an open chromatin structure characterized by DNA hypomethylation, abundant active histone modifications (e.g., H3 and H4 acetylation, H3K4 trimethylation, etc.), and low heterochromatin [36]. To maintain this unique chromatin state, PSCs have specific metabolic requirements, such as high levels of acetyl-CoA [37]. Treatment with acetyl-CoA precursor acetate increased H3K9/K27 acetylation labeling and delayed the early differentiation of hPSCs and mouse embryonic stem cells (mESCs), suggesting that decreased acetyl-CoA levels drive the differentiation of PSCs, possibly by reducing histone acetylation labeling and, thus, making chromatin more inaccessible [38]. A similar phenomenon




Fig. 1 Mitochondrial metabolites regulate the epigenetic landscape to determine stem cell fate. Historically, mitochondrial metabolism has been linked to the production of ATP and tricarboxylic acid cycle (TCA) metabolites to support stem cell survival and growth, respectively. However, it is now clear that beyond these canonical roles, mitochondria, as signaling organelles, dictate stem cell fate and function through TCA cycle metabolite production, NAD^+ / $NADH$ ratio modulation, and epigenetic regulation. Metabolites generated by the TCA cycle and one-carbon cycle act as substrates or cofactors to control epigenetic modification of stem cells, especially histone acetyla-

tion and methylation as well as DNA methylation. These metabolic cycles interact with each other like a gear, making the mitochondria a high-speed organelle that controls various life processes of stem cells. An imbalance in the ratio of mitochondrial metabolites can disrupt the normal function of stem cells. For example, an imbalance in the α -KG/succinic acid ratio or the NAD^+ / $NADH$ ratio can lead to changes in stem cell fate and function. α -KG alpha-ketoglutarate, NAD^+ nicotinamide adenine dinucleotide, $NADH$ NAD^+ hydrogen, SAM S-adenosylmethionine, TCA tricarboxylic acid

has been observed in muscle stem cells (MuSCs), where glucose-derived acetyl-CoA also influences their differentiation through histone acetylation [39].

In mesenchymal stem cells (MSCs), an unexpected age-dependent change in the localization of acetyl-lysine signaling was observed, shifting from the nucleus to the mitochondria during senescence [40]. Due to reduced levels of citrate carriers, acetyl-lysine was trapped within senescent MSC mitochondria, resulting in reduced histone acetylation and age-dependent chromatin tightening. Expression of exogenous citrate carriers or supplementation with acetate restores cell membrane acetyl-CoA levels, remodels the chromatin landscape and rejuvenates MSCs [40]. The findings of this study underscore the impact of communication between mitochondria and the nucleus on the process of stem cell senescence. Additionally, during the differentiation of neural stem cells (NSCs), the antiapoptotic gene TP53-inducible glycolysis and apoptosis regulator

(TIGAR) specifically modulates H3K9 acetylation by regulating the level of acetyl-CoA in cells and mitochondria, which determines the differentiation process of neural cells [41].

Recently, the emergence of non-histone acetylation has sparked a great deal of interest among biomedical researchers. Numerous studies have shown that non-histone protein acetylation plays a central role in various cellular processes related to physiology and disease [42]. However, the epigenetic regulation of stem cells is mainly focused on histone acetylation, with little attention given to the effects of non-histone acetylation. Therefore, further research is warranted to investigate this area.

Alpha-ketoglutarate

α -KG is a crucial intermediate in the TCA cycle, also known as the Krebs cycle, located between isocitrate and

succinyl-CoA. Remarkably, recent studies have highlighted the crucial role of α -KG in preserving the pluripotency of ESCs [43] and its potential application in anti-aging therapies [44]. Indeed, administering α -KG in a dose-dependent manner has been shown to extend the lifespan and delay the diminish of rapid, coordinated body movements in worms [44]. Wang and colleagues demonstrated that α -KG administration improved bone health in aged mice by increasing bone mass, reducing age-related bone loss, and accelerating bone regeneration. Additionally, α -KG treatment ameliorated the senescence-associated phenotypes of bone MSCs derived from aged mice while also enhancing their proliferation, colony formation, migration, and osteogenic potential [45]. The mechanism underlying the beneficial effects of α -KG on bone health involved a decrease in the accumulation of H3K9me3 and H3K27me3, which in turn led to an upregulation of bone morphogenetic protein (BMP) signaling and Nanog expression [45]. These findings shed light on the rejuvenating role of α -KG in MSCs and its potential for ameliorating age-related osteoporosis, highlighting its promising therapeutic potential for age-related diseases.

Ten–eleven translocation (TET) proteins play a key role in the demethylation of ESCs [46], and their absence leads to a decrease in pluripotency gene expression and an increase in the methylation level of their promoters, resulting in reduced cell pluripotency and cell differentiation [47]. Furthermore, overexpression of TET1 and TET2 has been shown to significantly improve induced pluripotent stem cell (iPSC) reprogramming in a catalytic-dependent manner. In these cells, α -KG maintains cellular pluripotency by controlling the level of histone H3K27me3 and TET-dependent DNA demethylation [43].

Studies have revealed that phosphoserine aminotransferase 1 (Psat1) plays a key role in maintaining intracellular α -KG levels in mESCs. The levels of Psat1 and α -KG have a direct impact on the timing of differentiation. By modulating α -KG levels at the onset of differentiation, an epigenetic landscape is created that is conducive to differentiation [48]. When ESCs are grown in the presence of signaling inhibitors to mitogen-activated protein kinase and glycogen synthase kinase, they utilize both glucose and glutamine in the medium to preserve high levels of α -KG to alter chromatin modifications [43, 49]. Compared with more differentiated cells, naïve ESCs utilize glucose and glutamine catabolism to maintain high intracellular levels of α -KG. When Psat1 levels are lowered, mESCs start to differentiate more quickly [50]. The study also found that α -KG levels decline during differentiation and that the dysregulation of α -KG impedes differentiation. In vitro, supplementation with cell-permeable α -KG directly supports ESC self-renewal. Importantly, treatment with cell-permeable dimethyl α -KG (DMKG) reverses the increases in the H3K27 and H4K20 trimethylation marks in

the mESCs, confirming that the increases in trimethylations are caused by a decline in α -KG levels in the cells [43]. Nevertheless, the enzymes that control α -KG production and how α -KG fine-tunes the fate of mESCs remain unclear. For NSCs, different levels of oxygen pressure and durations of hypoxic exposure determine the developmental process. The hydroxylation response activity of hypoxia-inducible factor (HIF) is controlled by α -KG [51].

Succinate and fumarate

In addition, succinate and fumarate, which are structurally similar to α -KG, competitively inhibit TETs and Histone lysine demethylases (KDMs), leading to the regulation of gene expression [52–54]. It was reported that in naïve embryonic stem cells, glutamine-derived α -KG helps sustain a high α -KG-to-succinate ratio, which is important for promoting histone/DNA demethylation and maintaining a highly accessible genome [50, 55]. Furthermore, succinate accumulation and, thereby, a decrease in the α -KG/succinate ratio induced by pharmacological inhibition or genetic knockdown of succinate dehydrogenase A (SDHA) delay primed hPSCs differentiation [56]. This effect can be rescued by DMKG treatment, which increases the α -KG/succinate ratio. An increase or decrease in the α -KG/succinate ratio also appears to regulate primed PSC fate by activating or inhibiting TET and KDM enzymes, respectively [56]. Recently, activation of succinate receptors on neural stem cells was shown to enhance their anti-inflammatory activity in an experimental model of autoimmune encephalomyelitis [57]. Interestingly, succinate may indirectly impact hematopoiesis in individuals with diabetes, as osteoclasts, which function as negative regulators of HSCs [58], may be influenced by succinate levels. In contrast, osteoblasts, which support lymphoid progenitors, may be less affected by succinate [59, 60]. Further research is necessary to confirm and expand upon these hypotheses.

NAD⁺/NADH

Nicotinamide adenine dinucleotide is a dietary compound essential for life and a coenzyme implicated in cellular redox reactions [61]. NAD⁺ and its reduced form, NAD⁺ hydrogen (NADH), are crucial for cellular function and genomic stability [61]. As a coenzyme for redox reactions, NAD⁺ is essential for key metabolic pathways, including the TCA cycle, the mitochondrial electron transport chain (ETC), glycolysis, and fatty acid β -oxidation. Mitochondria, as critical regulators of the cellular NAD⁺/NADH ratio, dictate the fate and function of different stem cells. Recent studies in yeast, worms, and mice have suggested that the activity of three different enzyme groups, namely, sirtuins (class III histone deacetylases), CD38 (cyclic ADP-ribose synthases),

and PARPs (poly ADP-ribose polymerases), are regulated by NAD^+/NADH [62–64]. Supplementation with NAD^+ in a nematode Werner syndrome model improved mitotic cell numbers and proliferation capacity, promoting nematode health and longevity, indicating enhanced stem cell function [65]. Notably, studies of sirtuins have yielded many exciting findings in recent years.

Sirtuins are conserved protein NAD-dependent deacetylases, and their functions are intrinsically linked to stem cell differentiation and senescence. When NAD^+ is deficient in nasopharyngeal carcinomas, their ability to differentiate and self-renew is impaired. NAD^+ levels in the hippocampus of mice decline with age and are highly correlated with NSCs dysfunction [66]. Sirt1 and Sirt2 redundantly mediate neural stem/progenitor cell fate decisions into oligodendrocytes [67]. Moreover, Gomes et al. reported that reduced levels of NAD^+ contribute to the mitochondrial decay associated with skeletal muscle aging and that SIRT1 modulates this process [68]. In aged mice, a decrease in NAD^+ levels in MuSCs leads to cell senescence, and boosting NAD^+ levels with the dietary precursor nicotinamide riboside alleviates MuSCs senescence and extends mouse lifespan [69]. A comparable occurrence was noted in HSCs, where the process was mediated by SIRT3 and SIRT7. The expression of SIRT3 and SIRT7 declines with age and leads to HSC dysfunction [70, 71]. Furthermore, overexpression of SIRT3 reduces oxidative stress and rescues functional defects in aged HSCs [70]. Expression of SIRT2, another SIRT family member, also decreases with age, which leads to chromatin silencing [72]. Activation of SIRT2 regulates signaling for mitochondrial stress in HSC, inhibits activation of NLRP3 inflammatory vesicles, and reverses functional deterioration in aging hematopoietic stem cells [73].

The NAD^+/NADH redox cycle, which plays a crucial role in energy production via glycolysis, the TCA cycle, and oxidative phosphorylation (OXPHOS), is also involved in regulating aging-related signaling pathways and functions [69, 74]. Human MSCs with damaged mitochondria exhibit depolarized mitochondrial membranes and low mitochondrial complex I function, which could compromise the ability to metabolize NADH and maintain NAD^+/NADH redox balance. This observation indicates that senescent hMSCs may shift toward a more reducing (or less oxidized) NAD^+/NADH cycle [75]. The ectopic expression of the single-subunit yeast alternative NADH dehydrogenase in *Drosophila* intestinal stem cells has been shown to delay the onset of intestinal aging and extend lifespan by modulating the NAD^+/NADH ratio in aged cells [76]. This suggests that the NAD^+/NADH ratio is a fundamental factor in cellular aging and lifespan. It is intriguing to investigate whether the role of NAD^+ and NADH dehydrogenases in age-related mitochondrial dysfunction is conserved in various tissues

and stem cells of different species and whether strategies to manipulate the NAD^+/NADH ratio in humans could have therapeutic benefits.

SAM

S-Adenosyl methionine (SAM) is a cofactor for histone methyltransferases connecting histone methylation to one-carbon metabolism [36] and threonine (Thr) metabolism [77]. DNA and histone methylations are driven by SAM as the methyl donor. Hence, mitochondrial metabolic fluctuation-induced changes in SAM levels may exert an influence on histone and DNA methylation, which are critical for maintaining cellular homeostasis and regulating lifespan [78].

The metabolic state of mouse ESCs is highly dependent on Thr catabolism. Recently, it was reported that Thr metabolism regulates intracellular SAM and histone methylation such that depletion of Thr from the culture medium or knockdown of threonine dehydrogenase (Tdh) in mouse ESCs decreases SAM accumulation and trimethylation of histone H3 lysine 4 (H3K4me3), leading to slowed growth and increased differentiation. Studies have shown that Thr metabolism regulates intracellular SAM and histone methylation [79, 80]. Removal of Thr from the medium or knockdown of Tdh reduced SAM accumulation and trimethylation of H3K4me3, resulting in slower growth and increased differentiation [79].

Naïve hPSCs also control SAM levels to regulate H3K4 trimethylation, which acts as a recognized signature marker of active chromatin [81]. This process links the metabolic and epigenetic regulation of pluripotent hPSCs. In a subsequent study, methionine deprivation was simulated under conditions of zinc deficiency in the culture medium, leading to a reduction in intracellular SAM and, thus, leaving PCs in a state of enhanced differentiation [82].


Stress signals affect epigenetic pathways in stem cell senescence

Environmental factors can easily impact the metabolic state of stem cells. Mitochondrial disruptions trigger stress signals and notify the nucleus of its functional state, resulting in adaptations. Various pathways are activated when mitochondrial function is impaired, including mitochondrial DNA (mtDNA) loss, mtDNA mutation accumulation, mitochondrial unfolded protein response (UPR^{mt}), and generation of ROS [83, 84] (Table 1). These stress-related changes can cause modifications to the epigenome and gene expression, leading to metabolic adaptation and increased lifespan of stem cells [85, 86] (Fig. 2). This section delves into how

Table 1 Mitochondrial stress response in stem cell proliferation, differentiation, and aging

| Stressor | Stem cell type | Cell activity | Effects | References |
|-------------------|--|--|---|---------------------|
| MtDNA mutation | NSCs, HPCs | Dysfunction | Anemia and lymphopenia | [87] |
| | ISCs | Abnormal proliferation Senescence | Impair intestinal function Reduce nutrient absorption | [88] |
| MtDNA mutation | HSCs | Inhibit differentiation | Hematopoietic abnormalities | [89] |
| | | | Defects in lymphopoiesis Myelodysplastic syndromes | [90] |
| MtDNA deletion | MuSCs | Dysfunction Increase senescence | Affect MuSCs pool Reduce regenerate and repair ability | [91] |
| ROS | HSCs | Regulate divisions Increase senescence | Regulate the differentiation | [92, 93] |
| | | | Reduce the replicative potential | [94] |
| | | | Affect FAO pathway Modulation cell divisions | [95] |
| | NSCs | Survival Proliferation | Maintain the quiescence and survival by FOXO proteins | [96] |
| | | | Increase Nrf2 expression and Transcription Regeneration of neurons | [97] |
| MSCs | Inhibit proliferation Increase senescence | Affect sirtuins expression and activity | [98] | |
| UPR ^{mt} | HSCs | Functional decline Maintain Proliferation | Downregulation of SIRT7 | [71] |
| | | | Increase mitochondrial protein Dysfunction | [99] |
| | MuSCs | Senescence | UPR ^{mt} is activated during the Transition from quiescence to Proliferation SOD2 activates UPR ^{mt} NR treatment can induce UPR ^{mt} Rejuvenate aged MuSCs | [100] [101, 102] |

Fig. 2 Roles of mitochondrial stress signaling responses in stem cells. Mitochondrial stress signaling responses play important roles in stem cells and are regulated by several key players, including mtDNA, ROS, and the UPR^{mt}. These stress-related changes result in modifications to the epigenome and gene expression, leading to metabolic adaptation and increased lifespan of stem cells [85, 86]. In a variety of stem cells, different mitochondrial stress responses are regulated to some extent by epigenetic changes. *mtDNA* mitochondrial DNA, *HSCs* hematopoietic stem cells, *MSCs* mesenchymal stem cells, *MuSCs* muscle stem cells, *NSCs* neural stem cells, *ROS* reactive oxygen species, *UPR^{mt}* mitochondrial unfolded protein response



mitochondrial stress signaling controls stem cell senescence through epigenetic regulation.

Mitochondrial DNA

Mitochondria possess multiple copies of their DNA. The 13 subunits of the mitochondrial respiratory chain enzymes as well as the 22 tRNAs and 2 rRNAs needed for the translation of these proteins are encoded by mtDNA [103].

The accumulation of damaged mitochondrial genomes is considered to be the underlying cause of age-related neurological and cardiovascular diseases, including Parkinson's disease and coronary artery disease [104–107]. Many studies have shown that altered mitochondrial DNA causes a reduction in stem cell populations and dysfunction, which is responsible for triggering aging and degenerative diseases. For instance, mtDNA polymerase gamma (POLG) mutant mice had NSC and hematopoietic progenitor cell (HPC) dysfunction from embryogenesis. HPCs showed abnormal lineage differentiation leading to anemia and lymphopenia [87]. Accelerated mitochondrial DNA mutations in stem cells of POLG mutant mice lead to impaired intestinal function and reduced nutrient absorption, which are important processes in aging [88]. In addition, the reprogramming ability of POLG mutant stem cells was significantly impaired during the generation of iPSCs [108]. McDonald et al. [109] showed that mtDNA mutations were present in stem cells of the normal human gastric epithelium and were passed on to differentiated progeny. Age-associated mitochondrial DNA mutations have also been reported to cause abnormal cell proliferation and apoptosis in human colonic crypts and inhibit the early differentiation of HSCs [89, 110]. In another mouse model of aging, systemic dysfunction of mitochondria due to mtDNA deletion affects the pool of muscle stem cells, thereby diminishing the muscle's capacity to regenerate and repair itself during the aging process [91]. Overall, these studies highlight the importance of mtDNA in controlling stem cell fate and function in a variety of contexts. Intact mitochondrial function is needed for appropriate multilineage stem cell differentiation. Notably, Norddahl et al. revealed that mitochondrial DNA mutations alone are not sufficient to cause age-related stem cell dysfunction [90].

Increasing evidence suggests that aberrant mtDNA modification plays an important role in disease development and progression [111–113]. Although mitochondria do not have histones, there are DNA–protein assemblies consisting of mtDNA [114]. A variety of nucleoid factors are involved in the maintenance and transcription of mtDNA, including mitochondrial transcription factor A (TFAM, the central mtDNA packaging factor), mitochondrial single-strand DNA binding protein (mtSSB), mitochondrial RNA polymerase (POLRMT), and Lon protease [115, 116]. Whether mtDNA

is modified by methylation has been controversial [111, 117]. Because methylase cannot enter mitochondria and mtDNA does not bind to histones, the prevailing view is that mtDNA cannot be methylated [118]. One study found that mtDNA methylation does not occur in the oocytes and early embryos of mice [119]. Recently, Tian et al. demonstrated that the mitochondrial genome undergoes DNA de novo methylation similar to the nuclear genome, which can help embryonic and somatic cells combat mtDNA damage triggered by mitochondrial oxidative stress and maintain mitochondrial genome stability [120]. Recent studies have implied that methylation can occur on cytosine and adenine residues in mtDNA, which is associated with aging and age-related diseases [121–123]. However, the methylation status of mtDNA remains a topic of controversy due to limitations in current methods for detection, as both CpG and non-CpG sites are present in mtDNA [124–126]. Many of the available methods for detecting mtDNA methylation have significant drawbacks [127]. mtDNA methylation changes to different degrees during development, aging, and hypoxic stress [127, 128], but the regulatory mechanism remains to be studied. Likewise, methylation of mtDNA regulates the activities of mitochondrial transcription factors. Methylation of mtDNA attenuates the binding of TFAM to the genome, thereby altering its transcriptional activity. This process may indirectly regulate the activities of TFB2M (transcription factor B2, mitochondrial) and POLRMT through the recruitment mechanism of TFAM [129]. Although the physiological role of mtDNA methylation is unknown, it has been found that aging reduces mtDNA 5-hydroxymethylcytosine (5hmC) in the frontal cortex of mice. In the same tissue, the expression of mitochondrial-encoded genes is upregulated with aging [130], suggesting that epigenetic regulation of mtDNA transcription is also involved in the aging process. In contrast, mtDNA methylation was not observed in mouse oocytes and early embryos [119]. This idea needs to be supported by more research.

Mitochondrial ROS

ROS refers to oxygen-containing free radicals or compounds that are more reactive than molecular oxygen, including superoxide radical anion (O_2^-), hydroxyl radical ($\cdot OH$), hydrogen peroxide (H_2O_2), and lipid hydroperoxides (LOOH) [131]. Mitochondria are a major source of ROS and central modulators of redox homeostasis in stem cells, a consequence of their role in energy (i.e., ATP) production via OXPHOS. Murphy has elaborated in detail on the process of ROS production by mitochondria [132, 133].

Impairment of the mitochondrial respiratory chain and inefficient OXPHOS can enhance electron leakage, leading to increased ROS generation. This detrimental

cycle can cause progressive and irreversible damage to cells, ultimately contributing to the aging process [134]. Mitochondria alter the epigenetic landscape via ROS, which play a particularly relevant role in regulating stem cell fate [6, 7]. The regenerative potential of stem cells is closely related to intracellular reactive oxygen species levels and cellular redox homeostasis [135].

The majority of mitochondrial ROS are produced due to electron leakage from OXPHOS complexes I and III, leading to damage to various cellular components, such as DNA, lipids, and proteins [136]. Stem cells appear to be particularly sensitive to elevated ROS levels. Under normal conditions, ROS function as signaling molecules that regulate the differentiation of stem/progenitor cells, such as in *Drosophila* hematopoietic cells [92]. Nevertheless, ROS levels increase in HSCs with age, and prolonged treatment with the antioxidant N-acetyl-L-cysteine (NAC) increases the replicative potential of HSCs upon serial transplantation in irradiated mice [93]. Another study demonstrated that *Bmi1*-deficient cells exhibit compromised mitochondrial function, elevated levels of reactive oxygen species, and activation of the DNA damage response pathway. However, these effects were ameliorated through NAC treatment [137]. Ito et al. provided evidence that mitochondrial ROS generation in HSCs and progenitors could be influenced by the fatty acid β -oxidation (FAO) pathway, leading to the modulation of symmetric and asymmetric HSC division [94]. Furthermore, Forkhead box O (FOXO) proteins, crucial mediators in ROS signaling, play an important role in the response to oxidative stress and are involved in preserving the quiescence and survival of HSCs [95]. Neural stem cells can eliminate ROS by upregulating *Nrf2* expression and transcription [96]. High ROS levels inhibit MSC proliferation and increase senescence. Modulating sirtuins expression and activity may reduce oxidative stress in MSCs [98]. Alterations in ROS levels may impact the expansion, depletion, and maintenance of stem cells.

Mitochondria altering the epigenetic landscape through ROS play a particularly pertinent role in regulating stem cell fate [138–140]. For instance, mitochondrial dysfunction induces histone hypermethylation by increasing the levels of ROS, which inhibits histone demethylases [2]. Neural stem cells exposed to the synthetic glucocorticoid dexamethasone or ROS have reduced overall DNA methylation and DNA methyltransferases, intimating the development of epigenetic alterations [141]. The generation of ROS is also associated with epigenetic chromatin modifications, including global DNA CpG hypomethylation and histone-3 phosphorylation, which promote cellular apoptosis and lead to hematopoietic catastrophe [142].

Although ROS are better known for their damaging properties, recent findings indicate that ROS may also be an integral physiological mediator of cellular signaling in

primary cells [143]. Intriguingly, the effects of mitochondrial ROS on stem cell dysfunction and aging are not all negative. Long-lived species do not always demonstrate lower levels of ROS [144]. A rise in ROS even increases the lifespan of worms [145]. Similarly, an increase in ROS levels is accompanied by an increase in mitochondrial size and ATP levels to protect HSCs from irradiation-induced apoptosis [146]. ROS production is an important component of neural stem cell regulation. The regeneration of dopamine neurons also depends on ROS production [97]. ROS signaling is considered to be an emerging key regulator of multiple stem cell populations [147]. Metabolic analysis has demonstrated that oxidative phosphorylation stimulates p38 mitogen-activated protein kinase (p38-MAPK) activation by mitochondrial reactive oxygen species signaling, thereby establishing the mature crypt phenotype. Hye Jin Jin et al. observed that senescent UCB-MSCs release monocyte chemoattractant protein 1 (MCP-1), a prominent chemokine, which facilitates the transmission of senescence signaling through its receptor chemokine (c-c motif) receptor 2 (CCR2), thereby promoting senescence by elevating the levels of p53 and p21 proteins via ROS or p38-MAPK signaling. Additionally, the polycomb protein BMI1 was found to downregulate the expression of MCP-1 by binding to its regulatory elements. As UCB-MSCs undergo senescence and BMI1 levels decrease, the epigenetic profile of MCP-1 changes, leading to the loss of H2AK119Ub and ultimately causing the derepression of MCP-1 [148]. This suggests that ROS signaling plays a critical role in the differentiation of stem cells in the small intestine [149]. Nevertheless, the effects of mtROS on stem cell function and the specific mechanisms remain to be further investigated.

Mitogen-activated protein kinases allow cells to interpret and respond to a wide variety of signals, such as changes in osmolarity, oxidative stress, and heat shock [150, 151]. Activation of MAPKs is associated with the ability to differentiate multiple types of stem cells in humans and mice [152–154]. In particular, all four p38 identified isoforms (p38 α , β , γ , and δ) serve as nexuses for signal transduction and play crucial roles in many biological processes [155, 156]. For stem cells, studies have indicated that the p38-MAPK pathway activated by ROS has a negative effect on the self-renewal and expansion of HSCs [155, 157]. SB203580 is a selective inhibitor of p38-MAPK. One possible mechanism is that SB203580 regulates the p38-MAPK signaling pathway by reducing the downstream phosphorylation of MAPKAPK2, HSP27, and ATF2 [158]. Administration of SB203580 helps HSCs recover the regenerative ability, maintain a static state, and promote expansion. [157, 159–161]. One recent study revealed that p38 α differentially modulates HSC function between the early and late progression phases of chronological aging [162]. During the early progression phase of chronological

aging, p38-MAPK activity maintains HSC repopulation capacity and multipotency after transplantation, whereas in the late progression phase, it decreases HSC repopulation capacity after transplantation [162]. The p38 pathway is also one of the major controllers that determines the fate of muscle stem cells by inducing the expression of muscle-specific genes [163]. The p38-MAPK pathway is also a key player in MSC senescence [164]. Inhibition of p38-MAPK signaling leads to improved regenerative properties of MSCs and their ability to support HSCs, even abrogating aging phenotypes [165, 166]. Prakash et al. found that depleting SIRT3 increases p38 signaling and promotes MSC death during oxidative stress [167]. Notably, in a later study, inhibition of p38 by SB203580 significantly impairs the lipid differentiation potential of MSCs [168], which diverges from the results obtained in the above study. This may be due to the different response of varied types or sources of stem cells to SB203580. As the major source of cancer initiation, relapse, and drug resistance, research on cancer stem cells (CSCs) has increased in recent years. For most cancers, inhibition of p38 can reduce the expression of stemness factors in CSCs and attenuate the invasion and metastasis of circulating tumor cells [169]. Another study suggested that the p38 pathway inhibits cancer development by inhibiting

cell proliferation and mediating cell senescence. Specifically, for non-small cell lung cancer cells, increased expression of WIP1 (wild-type p53-induced phosphatase) suppresses p38 activity and promotes CSCs properties by enhancing the expression of stemness-related transcription factors [170]. In a previous study, Shuhei Hattori demonstrated that the expression of EC-SOD (Extracellular-superoxide dismutase) in tubular-epithelial COS7 cells is downregulated through intracellular ROS signaling [171]. In line with this finding, treatment with CoCl_2 decreased the acetylation levels of histone H3 and H4 by activating intracellular ROS-p38-MAPK signaling. Additionally, luteolin effectively mitigated the reduction in EC-SOD caused by CoCl_2 by inhibiting ROS-p38-MAPK signaling and histone deacetylation [172]. Additionally, Arctigenin, a dietary phytoestrogen, has been identified as an inducer of apoptosis in MDA-MB-231 cells by activating the ROS/p38-MAPK pathway and regulating Bcl-2 through increased histone H3K9 trimethylation [173]. Nevertheless, further investigation is required to determine the potential involvement of CoCl_2 and Arctigenin in regulating the stem cells fate.

In summary, these studies reveal multifaceted functions of the p38-MAPK pathway in various contexts of multiple




Fig. 3 Roles of mitochondrial stress signaling responses in stem cells. Some pathways activated by stress signals, such as p38-MAPK and Wnt, control whether stem cells express stemness factors and affect

their differentiation and aging. This figure shows how related regulators (SIRT3/6, BMI1, SB203580, NCB-0846) influence these process through epigenetic pathways

stem cells (Fig. 3). Thus, regulating p38 might enable us to control the stem cell state and differentiation direction.

The UPR^{mt}

During aging, mitochondria will decline in function as a result of several factors. In cases of mitochondrial dysfunction, cells initiate a transcriptional response mechanism known as UPR^{mt}, which serves to regulate mitochondrial protein homeostasis [174]. UPR^{mt} was originally discovered in cultured mammalian cells where deletion of mtDNA or overexpression of mitochondrial targeting proteins triggered associated transcriptional responses, including mitochondrial molecular chaperones and quality control proteases [175, 176]. Studies in *C. elegans* have identified components in multiple subcellular compartments, providing insights into how cells detect mitochondrial dysfunction and communicate with the nucleus to adapt to transcription accordingly [177]. Importantly, this mitochondrial protein quality control mechanism is conserved among many species, including worms, mice, and humans [178–181]. However, the human UPR^{mt}, which is gaining relevance in a variety of physiological processes, remains not fully understood. The UPR^{mt} pathway not only triggers the transcription of chaperones and proteases to restore mitochondrial proteostasis but also renders cells more resistant to aging and metabolic stresses by inducing tolerance to mitochondrial stress [182, 183].

Following comprehensive research on the function and regulation of the UPR^{mt} in somatic cells, scientists have focused on exploring the regulatory mechanisms of the UPR^{mt} in stem cells. Mohrin et al. found that the reduction in *SIRT7* expression in aged HSCs leads to functional decline. The downregulation of *SIRT7* contributes to age-related functional degradation through an increase in mitochondrial protein dysfunction [71]. In line with this study, they further provide direct evidence that the mitochondrial UPR^{mt} is activated when hematopoietic stem cells transition from quiescence to proliferation [99]. This work has been recently extended into NSC aging. Wang et al. used single-cell RNA sequencing to analyze the dentate gyrus of young and aged mice and confirmed that mitochondrial protein folding stress is elevated as neural stem cells age. Among them, *SIRT7* overexpression inhibited mitochondrial protein folding stress to protect neural stem cells [184]. In addition to *SIRT7*, UPR^{mt} activation by superoxide dismutase 2 (SOD2) is imperative for HSCs to maintain the integrity of the mitochondrial network [100]. The expression of UPR^{mt}-associated genes can be affected by the level of cellular NAD⁺. NR (Nicotinamide riboside) treatment rejuvenated aged

MuSCs by inducing the mitochondrial unfolded protein response and synthesis of prohibition proteins [101, 102]. Moreover, intestinal epithelial-specific heat shock protein 60 (HSP60) deficiency triggers the UPR^{mt} pathway, which leads to the excessive proliferation of residual stem cells [185]. The findings indicate that the UPR^{mt} performs crucial functions in preserving adult stem cell populations in various tissues by ensuring metabolic robustness prior to committing to proliferation.

As a well-studied ‘old pathway’, Wnt signaling has been found to have a novel function in the UPR^{mt}. Highly conserved Wnt signaling is sufficiently required to mediate the involuntary activation of the UPR^{mt} in neuronal–intestinal cells [186]. Furthermore, there is a remarkable phenomenon wherein the UPR^{mt} induced by mitochondrial stress in neurons can be inherited by offspring [187]. Traditionally, the Wnt pathway is recognized as an important regulatory signaling axis that influences developmental processes in the embryo and regulates the maintenance, self-renewal, and differentiation of adult mammalian tissue stem cells [188]. In general, Wnt proteins act to maintain the undifferentiated state of stem cells [189]. Specifically, Wnt signaling regulates the metabolic requirements of neural crest-like stem cells through glycolysis and determines their differentiation [190]. There have been many advances in the epigenetic regulation of Wnt signaling in stem cells [191] (Fig. 3). For instance, the activation of the Wnt/ β -catenin signaling pathway ensures normal DNA methylation of mESCs, which is essential for differentiation and proliferation [192]. SIRT6 is a histone deacetylase that maintains Wnt signaling at a low level in HSCs by two methods: (1) deacetylating H3K56ac at the promoters of Wnt target genes and thereby inhibiting transcription; and (2) limiting signaling specificity by interacting with Wnt signaling factor TCF/LEF1. [193]. In addition, when Wnt signaling is activated by p38 β via LRP6 phosphorylation, this pathway maintains the self-renewal capacity of normal stem cells and cancer stem cells (CSCs) in many cell types [169]. A novel Wnt small molecule inhibitor NCB-0846 down-regulates the levels of LRP5 and LRP6 in colorectal cancer cells. NCB-0846 reduces the expression of Wnt downstream targets AXIN2 and cMYC and is expected to remove cancer stem cells [194]. What is more, the WNT protein is a critical cell reprogramming signaling molecule that can successfully reprogram fibroblasts or skin cells into induced pluripotent stem cells [195]. Given the important role of the Wnt/ β -catenin pathway in the pluripotent differentiation and regeneration of stem cells, further exploration of how Wnt signaling pathway-mediated UPR^{mt} in stem cells prolongs their lifespan is a promising direction of research.

Mitochondrial quality control and stem cell senescence

Mitochondria have evolved multiple mechanisms to ensure mitochondrial quality. These programs are dysregulated during physiological aging, which contributes to the functional deterioration of stem cells, tissue degeneration, and shortened organismal lifespan. A decline in mitochondrial quality control pathways results in a multitude of cellular malfunctions, including genetic and epigenetic changes. For example, Katarzyna Kornicka and her colleagues identified that the regulation of mitochondrial dynamics and autophagy by 5-azacytidine and resveratrol can reverse senescence and aging in adipose stem cells [196]. Specifically, 5-azacytidine/resveratrol treatment rejuvenates adipose stem cells isolated from equine metabolic syndrome (EMS) horses through epigenetic alternations [196]. Currently, several genes involved in mitophagy and mitochondrial dynamics have been identified to regulate stem cell activation and differentiation (Table 2).

Mitochondrial dynamics: fusion and fission

In higher eukaryotes, the segregation of mtDNA within cells is regulated by continuous cycles of mitochondrial fission and fusion. These processes are highly dynamic, and their


rates are finely tuned to meet the specific requirements of different cell types [217]. Mitochondrial dynamics is an important aspect of mitochondrial behavior that involves the processes of mitochondrial fission, fusion, tethering, and motility [218]. The balance between mitochondrial fission and fusion is critical for maintaining mitochondrial function and preventing cell death (Fig. 4) [219]. The alteration of mitochondrial dynamics leads to an increase in mitochondrial fission, which facilitates the process of mitophagy for the removal of damaged mitochondria and plays a role in driving cellular differentiation [220].

The use of mitochondria-specific probes, combined with fluorescence microscopy, has demonstrated that mitochondria are in the process of mitochondrial dynamics in mammalian cell lines and yeast [221]. The regulation of mitochondrial fusion is primarily achieved through three large proteins of GTPases situated on the mitochondrial membrane, namely, mitochondrial fusion proteins 1 and 2 (MFN1, MFN2) and optic nerve atrophy protein 1 (OPA1) [221, 222]. Conversely, the process of mitochondrial fission is controlled by a group of five proteins, which include dynamin-related protein 1 (DRP1), mitochondrial fission protein 1 (FIS1), mitochondrial fission factor (MFF), and mitochondrial elongation factors 1 and 2 (Mi49 and MiD51) [223]. Specifically, DRP1, which resides in the cytoplasm, plays an imperative role in the regulation of mitochondrial fission [224]. Upon receiving the fission signal, a

Table 2 Mitochondrial stress response in stem cell proliferation, differentiation, and aging

| Dynamics | Key genes | Manipulation | Effect on stem cell | References |
|-----------|---|---|---|---|
| Fusion | OPA1, MFN1/2 | Removal of MFN1 and MFN2 | Impair NSC self-renewal | [197] |
| | | | Block asymmetric division of stem cells | [198] |
| | | | Improve reprogramming efficiency and pluripotency | [199] |
| | | Gene trapping of MFN2 or OPA1 Removal of OPA1 Overexpression of MFN2 | Impair ESC differentiation | [200] |
| | | | Impair ISCs differentiation | [201] |
| | | | promote ESC differentiation | [202] |
| Fission | DRP1 FIS1, MFF, Mi49/51 | Downregulation of DRP1 | Promote hiPSCs differentiation | [203] |
| | | | Maintain HSCs stemness | [204] |
| | | | Rescue ISC differentiation defect | [205] |
| | | Upregulation of DRP1, FIS1 | Reduces the reprogramming efficiency of iPSCs | [206] |
| | | | MSCs lost differentiation potential | [207] |
| | | | Loss stemness | [208] |
| Mitophagy | PINK1, PARKIN, FUNDC1, BNIP3 AMBRA1 | Upregulation of PARKIN and PINK1 | Improve reprogramming efficiency of iPSCs | [209] |
| | | | Impair developmental potential | [210] |
| | | Upregulation of BNIP3 | Influence MSCs' differentiation direction | [207] |
| | | | Deficiency of PINK1 | Maintain stemness and regenerative capacity |
| | | Deficiency of SIRT1 | Induction of ISCs aging | [213] |
| | Lead to mitochondrial fragmentation and apoptosis | [214] | | |
| | Deficiency of PINK1 | Increase spontaneous differentiation and decrease reprogramming efficiency of iPSCs | [215] | |
| | Deficiency of SIRT1 | Delay activation of muscle stem cells | [216] | |

Fig. 4 Mitochondrial quality control in stem cells. The mitochondrial dynamic balance between fusion and fission maintains mitochondrial homeostasis, while damaged mitochondria are cleared via the mitophagy pathway or mitochondria-dependent apoptosis pathway. The alteration of mitochondrial dynamics leads to an increase in mitochondrial fission, which facilitates the process of mitophagy for the removal of damaged mitochondria and plays a role in driving cellular differentiation



considerable amount of DRP1 is transported to the outer membrane of mitochondria, where it interacts with FIS1, MFF, MiD49, and MiD51 to facilitate the process of mitochondrial fission [219]. Additionally, GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), as a mitochondrial outer membrane protein, plays a role in certain types of Charcot–Marie–Tooth disease and is also responsible for regulating mitochondrial fission [225]. However, the specific mechanism through which it accomplishes these actions remains unclear.

Mitochondrial dynamics induce the differentiation potential of pluripotent stem cells. Chen and Chan suggested that there is a relationship between the shape and structure of mitochondria and the ability of stem cells to mature into specialized cell types. Specifically, high levels of mitochondrial fission are associated with resistance to differentiation in some stem cells [226]. Loss of some key proteins leads to severe respiratory chain function, which may be essential for cell differentiation. Mitochondrial dynamics affect NSCs by regulating their self-renewal and fate decisions through transcriptional programming. Manipulation of mitochondrial structure impairs NSC self-renewal, leading to age-dependent depletion, neurogenesis defects, and cognitive impairments. Removal of *MFN1* and *MFN2* causes age-dependent attrition, neurogenesis deficits, and cognitive impairment in NSCs [197]. Additionally,

A recent study found that lower levels of SETD5 caused fragmentation in mitochondria and decreased mitochondrial membrane potential and ATP production in both neural precursors and neurons. And mutant neurons exhibited mislocalized mitochondria, with fewer organelles within neurites and synapses [227]. Gene trapping of *MFN2* or *OPA1* in mice arrested mouse heart development and impaired the differentiation of ESCs into cardiomyocytes [200]. *MFN1* interacts with a cell polarity protein complex to direct asymmetric cell division, allowing stem cell progeny to inherit fused mitochondria with enhanced reactive oxygen species scavenging capacity to sustain the stem cell pool [198]. *MFN2* is specifically needed for the maintenance of HSCs with extensive lymphoid potential [204]. *MFN2* also plays a role in inducing stem cell development. For example, knockdown of *MFN2* resulted in deficits in mitochondrial metabolism, whereas overexpression of *MFN2* enhanced mitochondrial bioenergetics and functions and promoted the differentiation of hiPSCs [203]. *MFN2*-induced mitochondrial elongation is sufficient to drive the exit of embryonic stem cells from initial pluripotency. This implies that *MFN2* plays a vital role in the transformation of mouse initial pluripotent cells to initiating pluripotent cells by promoting mitochondrial elongation [202]. The depletion of *MFN1/2* facilitates the transition of cells into a pluripotent state and sustains pluripotency through the coordinated

integration of Wnt or p53 signaling [199, 228] (Fig. 3). Knockdown of *OPA1* blocked enterocyte differentiation in intestinal stem/progenitor cells [201].

As with mitochondrial fusion, loss of mitochondrial fission results in stem cell fate changes. Dysfunction of DRP1 leads to mitochondrial fragmentation and impaired mitochondrial quality control [229]. Specifically, the induction of pluripotency is associated with mitochondrial fragmentation via the regulation of DRP1 phosphorylation [205]. Inhibition of DRP1 using a small molecule called mdivi-1 leads to the formation of a fused mitochondrial network. This greatly reduces the efficiency of reprogramming, thereby inhibiting the reprogramming of somatic cells to induced pluripotent stem cells [206]. The upregulation of *Fis1* expression during chondrogenesis implies that mitochondrial fragmentation plays a vital role in this differentiation process. The depletion of *Drp1* and *Fis1* resulted in a significant reduction in the differentiation potential of MSCs [207]. *Drp1* also helps CSCs of nasopharyngeal carcinoma (NPC) maintain stemness [208]. The possibility of DRP1 improving the reprogramming efficiency of iPSCs cannot be ruled out; thus, further investigation is required to fully understand its potential involvement [209]. Zhong et al. showed that excessive mitochondrial division regulated by DRP1 is associated with impaired embryonic developmental potential of stem cells. This indicates that the balance between mitochondrial fission and fusion regulated by DRP1 and other proteins is essential for the pluripotency of stem cells [210].

In contrast, Wang and colleagues discovered that knockdown of *Drp1* affected neither mitochondrial division and function nor ESC proliferation and pluripotency [230]. The defect in intestinal stem cell (ISC) differentiation could be rescued by concomitant inhibition of DRP1 [201]. Treatment with *Drp1*-specific inhibitors rescues mitochondrial function and apoptosis [231]. Downregulation of *Drp1* negatively affects the eventual differentiation of stem cells, particularly in the neurogenesis profile *in vitro* and *in vivo* [230]. Consequently, significant controversies persist concerning the mechanism by which DRP1 modulates stem cell fate. As mentioned above, mitochondrial fusion is involved in the regulation of stem cell pluripotency. However, the exact mechanisms involved are still being explored. The relationship between these factors requires further research for a comprehensive understanding.

Mitophagy

The concept of mitochondrial autophagy was first formalized in 2005 by Lemasters, who observed that loss of mitochondrial membrane potential and the opening of mitochondrial permeability pores could cause mitochondrial autophagy [232]. Mitophagy, along with mitochondrial

dynamics, plays a crucial role in maintaining a balance that preserves the quality control system of mitochondria.

Mitophagy regulatory pathways are classified as ubiquitin-dependent or ubiquitin independent [233]. The most studied mitophagy pathway involves mitochondrial serine/threonine PTEN-inducible kinase 1 (PINK1) and the cytoplasmic E3-ligase PARKIN [234–236]. In situations where mitochondria become damaged, there is typically a decrease in mitochondrial membrane potential, which triggers the activation of Parkin and PINK1 [237]. Initially, PINK1 starts to accumulate on the outer mitochondrial membrane. Once activated, PINK1 phosphorylates ubiquitin proteins that are minimally associated with outer mitochondrial membrane proteins. This process leads to an increase in Parkin levels on the outer mitochondrial membrane, which results in the continual formation of clustered ubiquitin chains by Parkin on outer mitochondrial membrane proteins [238]. Ubiquitin chain-tagged damaged mitochondria are recognized by a set of ubiquitin-bound mitochondrial autophagy receptors, resulting in Parkin-mediated degradation of mitochondrial outer membrane proteins [238]. In addition to Parkin, other ubiquitin E3 ligases are involved in the regulation of mitochondrial autophagy, either joining or acting in parallel with the Parkin/PINK1-mediated mitophagy pathway in a dendritic branching model [239, 240]. Furthermore, alternative pathways for mitophagy exist, which typically involve the recruitment of receptor molecules for LC3 family members on the outer mitochondrial membrane to identify and eliminate damaged mitochondria [241, 242]. These mechanisms mainly involve FUNDC1 (a mitochondrial autophagy receptor) regulated by hypoxia-inducible factor-1 (HIF-1), the mitochondrial outer membrane receptor BNIP3L/NIX (a mitochondrial protein belonging to the BCL2 family), and autophagy and Beclin 1 regulator 1 (AMBRA1) [243–245]. Despite the identification of numerous participants in mitophagy, the overall understanding is further complicated by significant overlap between these pathways.

There is increasing evidence highlighting the significance of mitophagy in maintaining stem cell homeostasis and promoting rejuvenation. For instance, adult human stem cells require intact mitophagy pathways for self-renewal and differentiation. The level of autophagy is higher in certain types of stem cells, including HSCs and skin stem cells, than in the surrounding cells [246]. HSCs maintain stem cell potential during cell cycling due to high mitochondrial clearance through the upregulation of Parkin and Pink1 [211, 212]. Loss of PINK1-dependent mitophagy led to a decrease in the efficiency of iPSC reprogramming and an increase in spontaneous differentiation [215]. Similarly, the reduction of Pink1 or Parkin in intestinal stem cells (ISCs) appears to lead to the induction of senescence, which in turn inhibits age-related loss of tissue homeostasis [213].

Moreover, BNIP3L/NIX is involved in mitophagy that occurs during reprogramming, which is important for iPSCs and is not dependent on mitochondrial membrane potential dissipation [247]. During the differentiation of MSCs into adipocytes and osteoblasts, autophagosome-forming proteins were significantly upregulated, indicating increased levels of autophagy. Additionally, the lipogenic capacity of MSCs was reduced after treatment with autophagy inhibitors [248]. Inhibition of autophagy leads to an increase in ROS accumulation and DNA damage, resulting in the loss of stemness in MSCs [249]. The nutrient sensor SIRT1 also plays a crucial role in regulating autophagy in muscle stem cell progeny. SIRT1 deficiency results in a delay in MuSCs activation, which is partially rescued by exogenous pyruvate. The loss of SIRT1 also leads to hyperacetylation of ATG7, a protein involved in autophagy [216]. Increasing evidence suggests that abnormal mitophagy can lead to senescence of bone marrow mesenchymal stem cells (BMSCs) [250, 251]. Targeting BMSC senescence can ameliorate osteoporosis, highlighting their potential as effective therapeutic interventions [252]. Intriguingly, Sirtuin-3 (Sirt3) is a crucial enzyme involved in regulating mitochondrial metabolism and maintaining mitochondrial homeostasis [253]. Brown et al. reported that the inhibition of Sirt3-mediated mitochondrial homeostasis contributes to increased oxidative stress in aged stem cells [70]. Most importantly, recent evidence has indicated that Sirt3 plays a protective role in mitigating senescence and sarcopenic obesity (SOP) induced by AGEs in BMSCs. In addition, targeting Sirt3 to enhance mitophagy could serve as a promising therapeutic approach to attenuate age-related SOP [254]. Additionally, the decline in autophagy in geriatric satellite cells leads to a loss of proteostasis, increased mitochondrial dysfunction, and oxidative stress, resulting in a decline in the function and number of satellite cells. Nevertheless, reestablishment of autophagy reverses senescence and restores regenerative functions in geriatric satellite cells [255]. In general, mitophagy-driven mitochondrial rejuvenation is required to induce and maintain stem cell pluripotency.

Emerging evidence suggests that mitochondrial dynamics and mitophagy are integrated systems [256–258] (Fig. 4). For example, as a master regulator of mitochondrial fission, Drp1 may play a role beyond the regulation of fission itself and is also considered to be an integral part of mitophagy [256]. After being ubiquitinated by Parkin, Drp1 promotes autophagy in damaged mitochondria [259]. Another previous study demonstrated that overexpression of Drp1 in HeLa cells resulted in a 70% reduction in mitochondrial mass, suggesting a direct link between mitochondrial division and mitophagy. Considering the size of mitochondria, only fragmented mitochondria can enter the autophagosome [260]. In contrast, an article published in 2021 observes that mitochondrial fission in primary neuronal cells exposed to

oxygen–glucose deprivation is a Drp1-dependent process, whereas mitochondrial clearance by mitophagy is not Drp1 dependent. A similar phenomenon has been observed in stem cells in recent years. Mitochondrial division promotes mitophagy in cancer stem cells [261]. Mitochondrial fission permits mitophagy in satellite cells during muscle regeneration [262]. However, the role of this relationship in other types of stem cells remains unclear.

Conclusions and perspectives

Mitochondria have evolved multiple mechanisms to ensure mitochondrial quality. These programs are dysregulated during physiological aging, which contributes to the functional deterioration of stem cells, tissue degeneration, and shortened organismal lifespan. A decline in mitochondrial quality control pathways results in a multitude of cellular malfunctions, including genetic and epigenetic changes. Currently, several genes involved in mitophagy and mitochondrial dynamics have been identified to regulate stem cell activation and differentiation (Table 2).

Mitochondria are essential organelles that play a crucial role in regulating stem cell fate. Both mitochondrial dysfunction and stem cell exhaustion have been the focus of considerable research in recent years. Evidence suggests that mitochondrial metabolites regulate various epigenetic changes that impact stem cell aging or differentiation by altering stress signaling levels or through quality control mechanisms. In this review, we elaborate on the crosstalk between mitochondrial and epigenetic changes in the modulation of stem cell fate. Understanding how mitochondria regulate stem cell fate is critical to the development of clinical-grade stem cells under strict quality control standards, contributing to the management of aging-associated organ dysfunction and disease.

Stem cells have promising applications in regenerative medicine and cell therapy. Researchers are dedicated to resolving how stem cells regulate their self-renewal, pluripotency, and plasticity. Maintaining stem cell stemness, controlling the direction of stem cell differentiation, preserving stem cell quality, and preventing their senescence are crucial aspects of stem cell research and its applications in regenerative medicine. Given the critical role of mitochondria in the induction and maintenance of stem cell pluripotency and cell differentiation, numerous researchers are striving to gain a comprehensive understanding of the mechanisms and roles of mitochondria in regulating the physiological functions of stem cells.

Despite the great progress that has been made, research in this field is still in the developmental stage. These relationships obtained thus far, like some threads, are insufficient to construct a mitochondrial network

that regulates the fate of stem cells. In particular, there are still overlaps and intersections between some relationships, and certain conclusions remain controversial and require further clarification [263]. This topic is also directly linked to several age-related diseases, such as Parkinson's disease, Alzheimer's disease, cancer, and other degenerative diseases. It is known that mitochondrial function decreases in several types of adult stem cells, but it remains unclear whether all types of stem cells, upon aging or differentiation, have similar mitochondrial and metabolic changes. Additionally, the identification of key regulators of the UPR^{mt}, mitophagy, and mitochondrial dynamics in different stem cells is one of the current research hotspots.

Modulating mitochondrial function or enhancing mitochondrial quality control may prove to be effective strategies for controlling stem cell amplification, stimulating stem cell activation for regenerative medicine, and combating stem cell dysfunction during the aging process. Notably, many aspects of mitochondrial regulation of stem cell function require additional research. Encouragingly, emerging tools of modern biology have made it easier to gain insight into this complex interaction. For example, simultaneous analysis of the genome, transcriptome, proteome, and metabolome to connect multiple levels of information has been successfully applied to the study of genetic reference populations. This multilayered study is also valuable for identifying the regulatory networks that govern stem cell function and fate decisions [264]. Another effective approach to study cellular diversity among stem cells is the use of emerging single-cell technologies such as single-cell RNA sequencing. This approach may be particularly relevant because of its high sensitivity and the limited availability of stem cells [265]. The application of these new technologies will undoubtedly provide stronger support in building mitochondrial regulatory networks and mapping stem cell epigenetic profiles.

Acknowledgements All figures were created with the help of an online drawing tool website named "Biorender" (<https://www.biorender.com/library>).

Author contributions Conceptualization, CZ, YM, JH; writing—original draft preparation, CS; writing—review and editing, YM and JH. All authors have read and agreed to the published version of the manuscript.

Funding This work is funded by grants from the National Key R&D Program of China (2022YFC1103702), the Fellowship of China National Postdoctoral Program for Innovative Talents, China Postdoctoral Science Foundation (BX20230244), the 1·3·5 Project for Disciplines of Excellence, West China Hospital (ZYGD23017, ZYJC21021), Natural Science Foundation of Sichuan (2023NSFSC0719) and the National Clinical Research Center for Geriatrics (Z20201007).

Data availability Please contact author for data requests.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethics approval and consent to participate Not applicable.

Consent for publication Not applicable.

References

1. Yang JH, Hayano M, Griffin PT, Amorim JA, Bonkowski MS, Apostolides JK et al (2023) Loss of epigenetic information as a cause of mammalian aging. *Cell* 186(2):305–26.e27. <https://doi.org/10.1016/j.cell.2022.12.027>
2. Matilainen O, Quirós PM, Auwerx J (2017) Mitochondria and epigenetics—crosstalk in homeostasis and stress. *Trends Cell Biol* 27(6):453–463. <https://doi.org/10.1016/j.tcb.2017.02.004>
3. Manev H, Dzitoyeva S (2013) Progress in mitochondrial epigenetics. *Biomol Concepts* 4(4):381–389. <https://doi.org/10.1515/bmc-2013-0005>
4. Chen K, Lu P, Beeraka NM, Sukocheva OA, Madhunapantula SV, Liu J et al (2022) Mitochondrial mutations and mitoepigenetics: focus on regulation of oxidative stress-induced responses in breast cancers. *Semin Cancer Biol* 83:556–569. <https://doi.org/10.1016/j.semcancer.2020.09.012>
5. Teslaa T, Teitell MA (2015) Pluripotent stem cell energy metabolism: an update. *Embo J* 34(2):138–153. <https://doi.org/10.15252/emboj.201490446>
6. Chakrabarty RP, Chandel NS (2021) Mitochondria as signaling organelles control mammalian stem cell fate. *Cell Stem Cell* 28(3):394–408. <https://doi.org/10.1016/j.stem.2021.02.011>
7. Spinelli JB, Zaganjor E (2022) Mitochondrial efficiency directs cell fate. *Nat Cell Biol* 24(2):125–126. <https://doi.org/10.1038/s41556-021-00834-3>
8. Avgustinova A, Benitah SA (2016) Epigenetic control of adult stem cell function. *Nat Rev Mol Cell Biol* 17(10):643–658. <https://doi.org/10.1038/nrm.2016.76>
9. Zhang H, Wang ZZ (2008) Mechanisms that mediate stem cell self-renewal and differentiation. *J Cell Biochem* 103(3):709–718. <https://doi.org/10.1002/jcb.21460>
10. Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK et al (2022) Stem cell-based therapy for human diseases. *Signal Transduct Target Ther* 7(1):272. <https://doi.org/10.1038/s41392-022-01134-4>
11. Biehl JK, Russell B (2009) Introduction to stem cell therapy. *J Cardiovasc Nurs* 24(2):98–103. <https://doi.org/10.1097/JCN.0b013e318197a6a5>
12. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S et al (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* 113(5):643–655. [https://doi.org/10.1016/s0092-8674\(03\)00392-1](https://doi.org/10.1016/s0092-8674(03)00392-1)
13. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R (2003) Multipotent cell lineages in early mouse development depend on SOX2 function. *Genes Dev* 17(1):126–140. <https://doi.org/10.1101/gad.224503>
14. Nichols J, Zevnik B, Anastasiadis K, Niwa H, Klewe-Nebenius D, Chambers I et al (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* 95(3):379–391. [https://doi.org/10.1016/s0092-8674\(00\)81769-9](https://doi.org/10.1016/s0092-8674(00)81769-9)

15. Atlasi Y, Stunnenberg HG (2017) The interplay of epigenetic marks during stem cell differentiation and development. *Nat Rev Genet* 18(11):643–658. <https://doi.org/10.1038/nrg.2017.57>
16. Avgustinova A, Benitah SA (2016) Epigenetic control of adult stem cell function. *Nat Rev Mol Cell Biol* 17:643–658
17. Shenoy A, Blelloch RH (2014) Regulation of microRNA function in somatic stem cell proliferation and differentiation. *Nat Rev Mol Cell Biol* 15(9):565–576. <https://doi.org/10.1038/nrm3854>
18. Martinez NJ, Gregory RI (2010) MicroRNA gene regulatory pathways in the establishment and maintenance of ESC identity. *Cell Stem Cell* 7(1):31–35. <https://doi.org/10.1016/j.stem.2010.06.011>
19. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. *Cell* 122:6–7
20. Hoppe T, Cohen E (2020) Organismal protein homeostasis mechanisms. *Genetics* 215(4):889–901. <https://doi.org/10.1534/genet.ics.120.301283>
21. Fernandez ME, Rutter RAC, Markham CM, Kok G (2019) Intervention mapping: theory- and evidence-based health promotion program planning: perspective and examples. *Front Public Health* 7:209. <https://doi.org/10.3389/fpubh.2019.00209>
22. Kapetanou M, Chondrogianni N, Petrakis S, Koliakos G, Gonos ES (2017) Proteasome activation enhances stemness and lifespan of human mesenchymal stem cells. *Free Radic Biol Med* 103:226–235. <https://doi.org/10.1016/j.freeradbiomed.2016.12.035>
23. Schröter F, Adjaye J (2014) The proteasome complex and the maintenance of pluripotency: sustain the fate by mopping up? *Stem Cell Res Ther* 5(1):24. <https://doi.org/10.1186/scri413>
24. Haws SA, Leech CM, Denu JM (2020) Metabolism and the epigenome: a dynamic relationship. *Trends Biochem Sci* 45(9):731–747. <https://doi.org/10.1016/j.tibs.2020.04.002>
25. Shyh-Chang N, Daley GQ, Cantley LC (2013) Stem cell metabolism in tissue development and aging. *Development* 140(12):2535–2547. <https://doi.org/10.1242/dev.091777>
26. Urbauer E, Rath E, Haller D (2020) Mitochondrial metabolism in the intestinal stem cell niche-sensing and signaling in health and disease. *Front Cell Dev Biol* 8:602814. <https://doi.org/10.3389/fcell.2020.602814>
27. Xu X, Duan S, Yi F, Ocampo A, Liu GH, Izpisua Belmonte JC (2013) Mitochondrial regulation in pluripotent stem cells. *Cell Metab* 18(3):325–332. <https://doi.org/10.1016/j.cmet.2013.06.005>
28. Dai Z, Ramesh V, Locasale JW (2020) The evolving metabolic landscape of chromatin biology and epigenetics. *Nat Rev Genet* 21(12):737–753. <https://doi.org/10.1038/s41576-020-0270-8>
29. Beerman I, Rossi DJ (2015) Epigenetic control of stem cell potential during homeostasis, aging, and disease. *Cell Stem Cell* 16(6):613–625. <https://doi.org/10.1016/j.stem.2015.05.009>
30. Martínez-Reyes I, Chandel NS (2020) Mitochondrial TCA cycle metabolites control physiology and disease. *Nat Commun* 11(1):102. <https://doi.org/10.1038/s41467-019-13668-3>
31. Ghosh-Choudhary S, Liu J, Finkel T (2020) Metabolic regulation of cell fate and function. *Trends Cell Biol* 30(3):201–212. <https://doi.org/10.1016/j.tcb.2019.12.005>
32. Takahashi H, McCaffery JM, Irizarry RA, Boeke JD (2006) Nucleocytosolic acetyl-coenzyme A synthetase is required for histone acetylation and global transcription. *Mol Cell* 23(2):207–217. <https://doi.org/10.1016/j.molcel.2006.05.040>
33. Mews P, Donahue G, Drake AM, Luczak V, Abel T, Berger SL (2017) Acetyl-CoA synthetase regulates histone acetylation and hippocampal memory. *Nature* 546(7658):381–386. <https://doi.org/10.1038/nature22405>
34. Sivanand S, Viney I, Wellen KE (2018) Spatiotemporal control of Acetyl-CoA metabolism in chromatin regulation. *Trends Biochem Sci* 43(1):61–74. <https://doi.org/10.1016/j.tibs.2017.11.004>
35. Umemoto T, Johansson A, Ahmad SAI, Hashimoto M, Kubota S, Kikuchi K et al (2022) ATP citrate lyase controls hematopoietic stem cell fate and supports bone marrow regeneration. *Embo J* 41(8):e109463. <https://doi.org/10.15252/embj.2021109463>
36. Mentch SJ, Mehrmohamadi M, Huang L, Liu X, Gupta D, Mattocks D et al (2015) Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. *Cell Metab* 22(5):861–873. <https://doi.org/10.1016/j.cmet.2015.08.024>
37. Wang J, Alexander P, Wu L, Hammer R, Cleaver O, McKnight SL (2009) Dependence of mouse embryonic stem cells on threonine catabolism. *Science* 325(5939):435–439. <https://doi.org/10.1126/science.1173288>
38. Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G, Barsch D et al (2015) Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. *Cell Metab* 21(3):392–402. <https://doi.org/10.1016/j.cmet.2015.02.002>
39. Das S, Morvan F, Morozzi G, Jourde B, Minetti GC, Kahle P et al (2017) ATP citrate lyase regulates myofiber differentiation and increases regeneration by altering histone acetylation. *Cell Rep* 21(11):3003–3011. <https://doi.org/10.1016/j.celrep.2017.11.038>
40. Pouikli A, Parekh S, Maleszewska M, Nikopoulou C, Baghdadi M, Tripodi I et al (2021) Chromatin remodeling due to degradation of citrate carrier impairs osteogenesis of aged mesenchymal stem cells. *Nature Aging*. 1(9):810. <https://doi.org/10.1038/s43587-021-00105-8>
41. Zhou W, Zhao T, Du J, Ji G, Li X, Ji S et al (2019) TIGAR promotes neural stem cell differentiation through acetyl-CoA-mediated histone acetylation. *Cell Death Dis* 10(3):198. <https://doi.org/10.1038/s41419-019-1434-3>
42. Narita T, Weinert BT, Choudhary C (2019) Functions and mechanisms of non-histone protein acetylation. *Nat Rev Mol Cell Biol* 20(3):156–174. <https://doi.org/10.1038/s41580-018-0081-3>
43. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB (2015) Intracellular α -ketoglutarate maintains the pluripotency of embryonic stem cells. *Nature* 518(7539):413–416. <https://doi.org/10.1038/nature13981>
44. Chin RM, Fu X, Pai MY, Vergnes L, Hwang H, Deng G et al (2014) The metabolite α -ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. *Nature* 510(7505):397–401. <https://doi.org/10.1038/nature13264>
45. Wang Y, Deng P, Liu Y, Wu Y, Chen Y, Guo Y et al (2020) Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. *Nat Commun* 11(1):5596. <https://doi.org/10.1038/s41467-020-19360-1>
46. Ficiz G, Hore TA, Santos F, Lee HJ, Dean W, Arand J et al (2013) FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. *Cell Stem Cell* 13(3):351–359. <https://doi.org/10.1016/j.stem.2013.06.004>
47. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappasilber J et al (2011) TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. *Nature* 473(7347):343–348. <https://doi.org/10.1038/nature10066>
48. Tran KA, Dillingham CM, Sridharan R (2019) The role of α -ketoglutarate-dependent proteins in pluripotency acquisition and maintenance. *J Biol Chem* 294(14):5408–5419. <https://doi.org/10.1074/jbc.TM118.000831>
49. Pasini D, Cloos PA, Walfridsson J, Olsson L, Bukowski JP, Johansen JV et al (2010) JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. *Nature* 464(7286):306–310. <https://doi.org/10.1038/nature08788>

50. Hwang IY, Kwak S, Lee S, Kim H, Lee SE, Kim JH et al (2016) Pstat1-dependent fluctuations in α -ketoglutarate affect the timing of ESC differentiation. *Cell Metab* 24(3):494–501. <https://doi.org/10.1016/j.cmet.2016.06.014>
51. Wong BW, Kuchnio A, Bruning U, Carmeliet P (2013) Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes. *Trends Biochem Sci* 38(1):3–11. <https://doi.org/10.1016/j.tibs.2012.10.004>
52. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR et al (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep* 12(5):463–469. <https://doi.org/10.1038/embor.2011.43>
53. Schvartzman JM, Thompson CB, Finley LWS (2018) Metabolic regulation of chromatin modifications and gene expression. *J Cell Biol* 217(7):2247–2259. <https://doi.org/10.1083/jcb.201803061>
54. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases. *Cancer Cell* 19(1):17–30. <https://doi.org/10.1016/j.ccr.2010.12.014>
55. Vardhana SA, Arnold PK, Rosen BP, Chen Y, Carey BW, Huangfu D et al (2019) Glutamine independence is a selectable feature of pluripotent stem cells. *Nat Metab* 1(7):676–687. <https://doi.org/10.1038/s42255-019-0082-3>
56. TeSlaa T, Chaikovskiy AC, Lipchina I, Escobar SL, Hochedlinger K, Huang J et al (2016) α -Ketoglutarate accelerates the initial differentiation of primed human pluripotent stem cells. *Cell Metab* 24(3):485–493. <https://doi.org/10.1016/j.cmet.2016.07.002>
57. Peruzzotti-Jametti L, Bernstock JD, Vicario N, Costa ASH, Kwok CK, Leonardi T et al (2018) Macrophage-derived extracellular succinate licenses neural stem cells to suppress chronic neuroinflammation. *Cell Stem Cell* 22(3):355–68.e13. <https://doi.org/10.1016/j.stem.2018.01.020>
58. Miyamoto K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y et al (2011) Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. *J Exp Med* 208(11):2175–2181. <https://doi.org/10.1084/jem.20101890>
59. Zhu X, Gui J, Dohkan J, Cheng L, Barnes PF, Su DM (2007) Lymphohematopoietic progenitors do not have a synchronized defect with age-related thymic involution. *Aging Cell* 6(5):663–672. <https://doi.org/10.1111/j.1474-9726.2007.00325.x>
60. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL (2004) Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. *Blood* 103(9):3258–3264. <https://doi.org/10.1182/blood-2003-11-4011>
61. Rajman L, Chwalek K, Sinclair DA (2018) Therapeutic potential of NAD-boosting molecules: the in vivo evidence. *Cell Metab* 27(3):529–547. <https://doi.org/10.1016/j.cmet.2018.02.011>
62. Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP et al (2017) NAD⁺ in aging: molecular mechanisms and translational implications. *Trends Mol Med* 23(10):899–916. <https://doi.org/10.1016/j.molmed.2017.08.001>
63. Imai S, Guarente L (2014) NAD⁺ and sirtuins in aging and disease. *Trends Cell Biol* 24(8):464–471. <https://doi.org/10.1016/j.tcb.2014.04.002>
64. Navas LE, Carnero A (2021) NAD⁺ metabolism, stemness, the immune response, and cancer. *Signal Transduct Target Ther* 6(1):2. <https://doi.org/10.1038/s41392-020-00354-w>
65. Fang EF, Hou Y, Lautrup S, Jensen MB, Yang B, SenGupta T et al (2019) NAD⁺ augmentation restores mitophagy and limits accelerated aging in Werner syndrome. *Nat Commun* 10(1):5284. <https://doi.org/10.1038/s41467-019-13172-8>
66. Yoshino J, Mills KF, Yoon MJ, Imai S (2011) Nicotinamide mononucleotide, a key NAD⁺ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. *Cell Metab* 14(4):528–536. <https://doi.org/10.1016/j.cmet.2011.08.014>
67. Stein LR, Imai S (2014) Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. *Embo J* 33(12):1321–1340. <https://doi.org/10.1002/embj.201386917>
68. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L et al (2013) Declining NAD⁺ induces a pseudo-hypoxic state disrupting nuclear-mitochondrial communication during aging. *Cell* 155(7):1624–1638. <https://doi.org/10.1016/j.cell.2013.11.037>
69. Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P et al (2016) NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. *Science* 352(6292):1436–1443. <https://doi.org/10.1126/science.aaf2693>
70. Brown K, Xie S, Qiu X, Mohrin M, Shin J, Liu Y et al (2013) SIRT3 reverses aging-associated degeneration. *Cell Rep* 3(2):319–327. <https://doi.org/10.1016/j.celrep.2013.01.005>
71. Mohrin M, Shin J, Liu Y, Brown K, Luo H, Xi Y et al (2015) Stem cell aging. A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. *Science* 347(6228):1374–1377. <https://doi.org/10.1126/science.aaa2361>
72. Chambers SM, Shaw CA, Gatz C, Fisk CJ, Donehower LA, Goodell MA (2007) Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. *PLoS Biol* 5(8):e201. <https://doi.org/10.1371/journal.pbio.0050201>
73. Luo H, Mu WC, Karki R, Chiang HH, Mohrin M, Shin JJ et al (2019) Mitochondrial stress-initiated aberrant activation of the NLRP3 inflammasome regulates the functional deterioration of hematopoietic stem cell aging. *Cell Rep* 26(4):945–54.e4. <https://doi.org/10.1016/j.celrep.2018.12.101>
74. Xiao W, Wang RS, Handy DE, Loscalzo J (2018) NAD(H) and NADP(H) redox couples and cellular energy metabolism. *Antioxid Redox Signal* 28(3):251–272. <https://doi.org/10.1089/ars.2017.7216>
75. Yuan X, Liu Y, Bijonowski BM, Tsai AC, Fu Q, Logan TM et al (2020) NAD⁺/NADH redox alterations reconfigure metabolism and rejuvenate senescent human mesenchymal stem cells in vitro. *Commun Biol* 3(1):774. <https://doi.org/10.1038/s42003-020-01514-y>
76. Hur JH, Bahadorani S, Graniel J, Koehler CL, Ulgherait M, Rera M et al (2013) Increased longevity mediated by yeast NDI1 expression in *Drosophila* intestinal stem and progenitor cells. *Aging (Albany NY)* 5(9):662–681. <https://doi.org/10.18632/aging.100595>
77. Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrao S et al (2013) Influence of threonine metabolism on S-adenosylmethionine and histone methylation. *Science* 339(6116):222–226. <https://doi.org/10.1126/science.1226603>
78. Saul D, Kosinsky RL (2021) Epigenetics of aging and aging-associated diseases. *Int J Mol Sci* 22(1):401
79. Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrao S et al (2013) Influence of threonine metabolism on S-adenosylmethionine and histone methylation. *Science* 339(6116):222–226. <https://doi.org/10.1126/science.1226603>
80. Chen G, Wang J (2019) A regulatory circuitry locking pluripotent stemness to embryonic stem cell: interaction between threonine catabolism and histone methylation. *Semin Cancer Biol* 57:72–78. <https://doi.org/10.1016/j.semcancer.2019.01.005>
81. Shiraki N, Shiraki Y, Tsuyama T, Obata F, Miura M, Nagae G et al (2014) Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. *Cell Metab* 19(5):780–794. <https://doi.org/10.1016/j.cmet.2014.03.017>
82. Sim EZ, Enomoto T, Shiraki N, Furuta N, Kashio S, Kambe T et al (2022) Methionine metabolism regulates pluripotent stem cell pluripotency and differentiation through zinc mobilization.

- Cell Rep 40(3):111120. <https://doi.org/10.1016/j.celrep.2022.111120>
83. Melber A, Haynes CM (2018) UPR(mt) regulation and output: a stress response mediated by mitochondrial-nuclear communication. *Cell Res* 28(3):281–295. <https://doi.org/10.1038/cr.2018.16>
 84. Quirós PM, Mottis A, Auwerx J (2016) Mitonuclear communication in homeostasis and stress. *Nat Rev Mol Cell Biol* 17(4):213–226. <https://doi.org/10.1038/nrm.2016.23>
 85. Tabibzadeh S (2021) Signaling pathways and effectors of aging. *Front Biosci (Landmark Ed)* 26(1):50–96. <https://doi.org/10.2741/4889>
 86. English J, Son JM, Cardamone MD, Lee C, Perissi V (2020) Decoding the rosetta stone of mitonuclear communication. *Pharmacol Res* 161:105161. <https://doi.org/10.1016/j.phrs.2020.105161>
 87. Ahlqvist KJ, Hämäläinen RH, Yatsuga S, Uutela M, Terzioglu M, Götz A et al (2012) Somatic progenitor cell vulnerability to mitochondrial DNA mutagenesis underlies progeroid phenotypes in Polg mutator mice. *Cell Metab* 15(1):100–109. <https://doi.org/10.1016/j.cmet.2011.11.012>
 88. Fox RG, Magness S, Kujoth GC, Prolla TA, Maeda N (2012) Mitochondrial DNA polymerase editing mutation, PolgD257A, disturbs stem-progenitor cell cycling in the small intestine and restricts excess fat absorption. *Am J Physiol Gastrointest Liver Physiol* 302(9):G914–G924. <https://doi.org/10.1152/ajpgi.00402.2011>
 89. Chen ML, Logan TD, Hochberg ML, Shelat SG, Yu X, Wilding GE et al (2009) Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. *Blood* 114(19):4045–4053. <https://doi.org/10.1182/blood-2008-08-169474>
 90. Norddahl GL, Pronk CJ, Wahlestedt M, Sten G, Nygren JM, Ugale A et al (2011) Accumulating mitochondrial DNA mutations drive premature hematopoietic aging phenotypes distinct from physiological stem cell aging. *Cell Stem Cell* 8(5):499–510. <https://doi.org/10.1016/j.stem.2011.03.009>
 91. Wang X, Pickrell AM, Rossi SG, Pinto M, Dillon LM, Hida A et al (2013) Transient systemic mtDNA damage leads to muscle wasting by reducing the satellite cell pool. *Hum Mol Genet* 22(19):3976–3986. <https://doi.org/10.1093/hmg/ddt251>
 92. Owusu-Ansah E, Banerjee U (2009) Reactive oxygen species prime *Drosophila* haematopoietic progenitors for differentiation. *Nature* 461(7263):537–541. <https://doi.org/10.1038/nature08313>
 93. Nagata M, Arimitsu N, Ito T, Sekimizu K (2007) Antioxidant N-acetyl-L-cysteine inhibits erythropoietin-induced differentiation of erythroid progenitors derived from mouse fetal liver. *Cell Biol Int* 31(3):252–256. <https://doi.org/10.1016/j.cellbi.2006.11.001>
 94. Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE et al (2012) A PML–PPAR- δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. *Nat Med* 18(9):1350–1358. <https://doi.org/10.1038/nm.2882>
 95. Eijkelenboom A, Burgering BM (2013) FOXOs: signalling integrators for homeostasis maintenance. *Nat Rev Mol Cell Biol* 14(2):83–97. <https://doi.org/10.1038/nrm3507>
 96. Kahroba H, Ramezani B, Maadi H, Sadeghi MR, Jaberie H, Ramezani F (2021) The role of Nrf2 in neural stem/progenitors cells: from maintaining stemness and self-renewal to promoting differentiation capability and facilitating therapeutic application in neurodegenerative disease. *Ageing Res Rev* 65:101211. <https://doi.org/10.1016/j.arr.2020.101211>
 97. Hameed LS, Berg DA, Belnoue L, Jensen LD, Cao Y, Simon A (2015) Environmental changes in oxygen tension reveal ROS-dependent neurogenesis and regeneration in the adult newt brain. *Elife*. <https://doi.org/10.7554/eLife.08422>
 98. Denu RA, Hematti P (2016) Effects of oxidative stress on mesenchymal stem cell biology. *Oxid Med Cell Longev* 2016:2989076. <https://doi.org/10.1155/2016/2989076>
 99. Mohrin M, Widjaja A, Liu Y, Luo H, Chen D (2018) The mitochondrial unfolded protein response is activated upon hematopoietic stem cell exit from quiescence. *Ageing Cell* 17(3):e12756. <https://doi.org/10.1111/acel.12756>
 100. He C, Hart PC, Germain D, Bonini MG (2016) SOD2 and the mitochondrial UPR: partners regulating cellular phenotypic transitions. *Trends Biochem Sci* 41(7):568–577. <https://doi.org/10.1016/j.tibs.2016.04.004>
 101. Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P et al (2016) NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. *Science* 352(6292):1436–1443. <https://doi.org/10.1126/science.aaf2693>
 102. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C et al (2013) The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. *Cell* 154(2):430–441. <https://doi.org/10.1016/j.cell.2013.06.016>
 103. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J et al (1981) Sequence and organization of the human mitochondrial genome. *Nature* 290(5806):457–465. <https://doi.org/10.1038/290457a0>
 104. Duarte JM, Schuck PF, Wenk GL, Ferreira GC (2014) Metabolic disturbances in diseases with neurological involvement. *Ageing Dis* 5(4):238–255. <https://doi.org/10.14336/ad.2014.0500238>
 105. Krzywanski DM, Moellering DR, Fetterman JL, Dunham-Snary KJ, Sammy MJ, Ballinger SW (2011) The mitochondrial paradigm for cardiovascular disease susceptibility and cellular function: a complementary concept to Mendelian genetics. *Lab Invest* 91(8):1122–1135. <https://doi.org/10.1038/labinvest.2011.95>
 106. Ballinger SW (2005) Mitochondrial dysfunction in cardiovascular disease. *Free Radic Biol Med* 38(10):1278–1295. <https://doi.org/10.1016/j.freeradbiomed.2005.02.014>
 107. Kauppila TES, Kauppila JHK, Larsson NG (2017) Mammalian mitochondria and aging: an update. *Cell Metab* 25(1):57–71. <https://doi.org/10.1016/j.cmet.2016.09.017>
 108. Hämäläinen RH, Ahlqvist KJ, Ellonen P, Lepistö M, Logan A, Otonkoski T et al (2015) mtDNA mutagenesis disrupts pluripotent stem cell function by altering redox signaling. *Cell Rep* 11(10):1614–1624. <https://doi.org/10.1016/j.celrep.2015.05.009>
 109. McDonald SA, Greaves LC, Gutierrez-Gonzalez L, Rodriguez-Justo M, Deheragoda M, Leedham SJ et al (2008) Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. *Gastroenterology* 134(2):500–510. <https://doi.org/10.1053/j.gastro.2007.11.035>
 110. Taylor RW, Barron MJ, Borthwick GM, Gospel A, Chinnery PF, Samuels DC et al (2003) Mitochondrial DNA mutations in human colonic crypt stem cells. *J Clin Invest* 112(9):1351–1360. <https://doi.org/10.1172/jci19435>
 111. Iacobazzi V, Castegna A, Infantino V, Andria G (2013) Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool. *Mol Genet Metab* 110(1–2):25–34. <https://doi.org/10.1016/j.ymgme.2013.07.012>
 112. Bacalini MG, D’Aquila P, Marasco E, Nardini C, Montesanto A, Franceschi C et al (2017) The methylation of nuclear and mitochondrial DNA in ageing phenotypes and longevity. *Mech Ageing Dev* 165(Pt B):156–161. <https://doi.org/10.1016/j.mad.2017.01.006>
 113. Stocco A, Mosca L, Carnicelli V, Cavallari U, Lunetta C, Marocchi A et al (2018) Mitochondrial DNA copy number and D-loop region methylation in carriers of amyotrophic lateral

- sclerosis gene mutations. *Epigenomics* 10(11):1431–1443. <https://doi.org/10.2217/epi-2018-0072>
114. Gilkerson R, Bravo L, Garcia I, Gaytan N, Herrera A, Maldonado A et al (2013) The mitochondrial nucleoid: integrating mitochondrial DNA into cellular homeostasis. *Cold Spring Harb Perspect Biol* 5(5):a011080. <https://doi.org/10.1101/cshperspect.a011080>
 115. Bogenhagen DF, Rousseau D, Burke S (2008) The layered structure of human mitochondrial DNA nucleoids. *J Biol Chem* 283(6):3665–3675. <https://doi.org/10.1074/jbc.M708444200>
 116. Kukat C, Davies KM, Wurm CA, Spähr H, Bonekamp NA, Köhl I et al (2015) Cross-strand binding of TFAM to a single mtDNA molecule forms the mitochondrial nucleoid. *Proc Natl Acad Sci U S A* 112(36):11288–11293. <https://doi.org/10.1073/pnas.1512131112>
 117. Shmookler Reis RJ, Goldstein S (1983) Mitochondrial DNA in mortal and immortal human cells. Genome number, integrity, and methylation. *J Biol Chem* 258(15):9078–9085
 118. Satoh M, Kuroiwa T (1991) Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell. *Exp Cell Res* 196(1):137–140. [https://doi.org/10.1016/0014-4827\(91\)90467-9](https://doi.org/10.1016/0014-4827(91)90467-9)
 119. Fan L-H, Wang Z-B, Li Q-N, Meng T-G, Dong M-Z, Hou Y et al (2019) Absence of mitochondrial DNA methylation in mouse oocyte maturation, aging and early embryo development. *Biochem Biophys Res Commun* 513(4):912–918. <https://doi.org/10.1016/j.bbrc.2019.04.100>
 120. Yue Y, Ren L, Zhang C, Miao K, Tan K, Yang Q et al (2022) Mitochondrial genome undergoes de novo DNA methylation that protects mtDNA against oxidative damage during the peri-implantation window. *Proc Natl Acad Sci U S A* 119(30):e2201168119. <https://doi.org/10.1073/pnas.2201168119>
 121. Boulias K, Greer EL (2023) Biological roles of adenine methylation in RNA. *Nat Rev Genet* 24(3):143–160. <https://doi.org/10.1038/s41576-022-00534-0>
 122. Boulias K, Greer EL (2022) Means, mechanisms and consequences of adenine methylation in DNA. *Nat Rev Genet* 23(7):411–428. <https://doi.org/10.1038/s41576-022-00456-x>
 123. Stoccoro A, Coppèdè F (2021) Mitochondrial DNA methylation and human diseases. *Int J Mol Sci*. <https://doi.org/10.3390/ijms22094594>
 124. Patil V, Cuenin C, Chung F, Aguilera JRR, Fernandez-Jimenez N, Romero-Garmendia I et al (2019) Human mitochondrial DNA is extensively methylated in a non-CpG context. *Nucleic Acids Res* 47(19):10072–10085. <https://doi.org/10.1093/nar/gkz762>
 125. van der Wijst MG, van Tilburg AY, Ruiters MH, Rots MG (2017) Experimental mitochondria-targeted DNA methylation identifies GpC methylation, not CpG methylation, as potential regulator of mitochondrial gene expression. *Sci Rep* 7(1):177. <https://doi.org/10.1038/s41598-017-00263-z>
 126. Bellizzi D, D'Aquila P, Scafone T, Giordano M, Riso V, Riccio A et al (2013) The control region of mitochondrial DNA shows an unusual CpG and non-CpG methylation pattern. *DNA Res* 20(6):537–547. <https://doi.org/10.1093/dnares/dst029>
 127. van der Wijst MG, Rots MG (2015) Mitochondrial epigenetics: an overlooked layer of regulation? *Trends Genet* 31(7):353–356. <https://doi.org/10.1016/j.tig.2015.03.009>
 128. Dou X, Boyd-Kirkup JD, McDermott J, Zhang X, Li F, Rong B et al (2019) The strand-biased mitochondrial DNA methylome and its regulation by DNMT3A. *Genome Res* 29(10):1622–1634. <https://doi.org/10.1101/gr.234021.117>
 129. Dostal V, Churchill MEA (2019) Cytosine methylation of mitochondrial DNA at CpG sequences impacts transcription factor A DNA binding and transcription. *Biochim Biophys Acta Gene Regul Mech* 1862(5):598–607. <https://doi.org/10.1016/j.bbagr.2019.01.006>
 130. Dzitoyeva S, Chen H, Manev H (2012) Effect of aging on 5-hydroxymethylcytosine in brain mitochondria. *Neurobiol Aging* 33(12):2881–2891. <https://doi.org/10.1016/j.neurobiolaging.2012.02.006>
 131. Cadenas E, Davies KJ (2000) Mitochondrial free radical generation, oxidative stress, and aging. *Free Radic Biol Med* 29(3–4):222–230. [https://doi.org/10.1016/s0891-5849\(00\)00317-8](https://doi.org/10.1016/s0891-5849(00)00317-8)
 132. Murphy MP (2009) How mitochondria produce reactive oxygen species. *Biochem J* 417(1):1–13. <https://doi.org/10.1042/bj20081386>
 133. Li J, Zhang J, Chen Y, Kawazoe N, Chen G (2017) TEMPO-conjugated gold nanoparticles for reactive oxygen species scavenging and regulation of stem cell differentiation. *ACS Appl Mater Interfaces* 9(41):35683–35692. <https://doi.org/10.1021/acsami.7b12486>
 134. Harman D (1972) The biologic clock: the mitochondria? *J Am Geriatr Soc* 20(4):145–147. <https://doi.org/10.1111/j.1532-5415.1972.tb00787.x>
 135. Tan DQ, Suda T (2018) Reactive oxygen species and mitochondrial homeostasis as regulators of stem cell fate and function. *Antioxid Redox Signal* 29(2):149–168. <https://doi.org/10.1089/ars.2017.7273>
 136. Zhang H, Menzies KJ, Auwerx J (2018) The role of mitochondria in stem cell fate and aging. *Development*. <https://doi.org/10.1242/dev.143420>
 137. Liu J, Cao L, Chen J, Song S, Lee IH, Quijano C et al (2009) Bmi1 regulates mitochondrial function and the DNA damage response pathway. *Nature* 459(7245):387–392. <https://doi.org/10.1038/nature08040>
 138. Mishra BP, Zaffuto KM, Artinger EL, Org T, Mikkola HK, Cheng C et al (2014) The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. *Cell Rep* 7(4):1239–1247. <https://doi.org/10.1016/j.celrep.2014.04.015>
 139. Rimmelé P, Bigarella CL, Liang R, Izac B, Dieguez-Gonzalez R, Barbet G et al (2014) Aging-like phenotype and defective lineage specification in SIRT1-deleted hematopoietic stem and progenitor cells. *Stem Cell Reports* 3(1):44–59. <https://doi.org/10.1016/j.stemcr.2014.04.015>
 140. Huang M, Wu Q, Jiang ZH (2022) Epigenetic alterations under oxidative stress in stem cells. *Oxid Med Cell Longev* 2022:6439097. <https://doi.org/10.1155/2022/6439097>
 141. Bose R, Moors M, Tofighi R, Cascante A, Hermanson O, Cecatelli S (2010) Glucocorticoids induce long-lasting effects in neural stem cells resulting in senescence-related alterations. *Cell Death Dis* 1(11):e92. <https://doi.org/10.1038/cddis.2010.60>
 142. Chatterjee R, Law S (2018) Epigenetic and microenvironmental alterations in bone marrow associated with ROS in experimental aplastic anemia. *Eur J Cell Biol* 97(1):32–43. <https://doi.org/10.1016/j.ejcb.2017.11.003>
 143. Chandel NS (2015) Evolution of mitochondria as signaling organelles. *Cell Metab* 22(2):204–206. <https://doi.org/10.1016/j.cmet.2015.05.013>
 144. Chen JH, Hales CN, Ozanne SE (2007) DNA damage, cellular senescence and organismal ageing: causal or correlative? *Nucleic Acids Res* 35(22):7417–7428. <https://doi.org/10.1093/nar/gkm681>
 145. Zarse K, Schmeisser S, Groth M, Priebe S, Beuster G, Kuhlow D et al (2012) Impaired insulin/IGF1 signaling extends life span by promoting mitochondrial L-proline catabolism to induce a transient ROS signal. *Cell Metab* 15(4):451–465. <https://doi.org/10.1016/j.cmet.2012.02.013>
 146. Maryanovich M, Zaltsman Y, Ruggiero A, Goldman A, Shachnai L, Zaidman SL et al (2015) An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem

- cell fate. *Nat Commun* 6:7901. <https://doi.org/10.1038/ncomms8901>
147. Bigarella CL, Liang R, Ghaffari S (2014) Stem cells and the impact of ROS signaling. *Development* 141(22):4206–4218. <https://doi.org/10.1242/dev.107086>
 148. Jin HJ, Lee HJ, Heo J, Lim J, Kim M, Kim MK et al (2016) Senescence-associated MCP-1 secretion is dependent on a decline in BMI1 in human mesenchymal stromal cells. *Antioxid Redox Signal* 24(9):471–485. <https://doi.org/10.1089/ars.2015.6359>
 149. Rodríguez-Colman MJ, Schewe M, Meerlo M, Stigter E, Gerrits J, Pras-Raves M et al (2017) Interplay between metabolic identities in the intestinal crypt supports stem cell function. *Nature* 543(7645):424–427. <https://doi.org/10.1038/nature21673>
 150. Gui T, Sun Y, Shimokado A, Muragaki Y (2012) The roles of mitogen-activated protein kinase pathways in TGF- β -induced epithelial-mesenchymal transition. *J Signal Transduct* 2012:289243. <https://doi.org/10.1155/2012/289243>
 151. Martínez-Limón A, Joaquín M, Caballero M, Posas F, de Nadal E (2020) The p38 pathway: from biology to cancer therapy. *Int J Mol Sci*. <https://doi.org/10.3390/ijms21061913>
 152. Bhandari DR, Seo KW, Roh KH, Jung JW, Kang SK, Kang KS (2010) REX-1 expression and p38 MAPK activation status can determine proliferation/differentiation fates in human mesenchymal stem cells. *PLoS ONE* 5(5):e10493. <https://doi.org/10.1371/journal.pone.0010493>
 153. Brien P, Pugazhendhi D, Woodhouse S, Oxley D, Pell JM (2013) p38 α MAPK regulates adult muscle stem cell fate by restricting progenitor proliferation during postnatal growth and repair. *Stem Cells* 31(8):1597–1610. <https://doi.org/10.1002/stem.1399>
 154. Charville GW, Cheung TH, Yoo B, Santos PJ, Lee GK, Shrager JB et al (2015) Ex vivo expansion and in vivo self-renewal of human muscle stem cells. *Stem Cell Rep* 5(4):621–632. <https://doi.org/10.1016/j.stemcr.2015.08.004>
 155. He Y, She H, Zhang T, Xu H, Cheng L, Yepes M et al (2018) p38 MAPK inhibits autophagy and promotes microglial inflammatory responses by phosphorylating ULK1. *J Cell Biol* 217(1):315–328. <https://doi.org/10.1083/jcb.201701049>
 156. Xiong Y, Collins QF, An J, Lupo E Jr, Liu HY, Liu D et al (2007) p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. *J Biol Chem* 282(7):4975–4982. <https://doi.org/10.1074/jbc.M606742200>
 157. Jung H, Kim DO, Byun J-E, Kim WS, Kim MJ, Song HY et al (2016) Thioredoxin-interacting protein regulates haematopoietic stem cell ageing and rejuvenation by inhibiting p38 kinase activity. *Nat Commun* 7(1):13674. <https://doi.org/10.1038/ncomms13674>
 158. Sreekanth GP, Chuncharunee A, Sirimontaporn A, Panaampon J, Noisakran S, Yenchitsomanus PT et al (2016) SB203580 modulates p38 MAPK signaling and dengue virus-induced liver injury by reducing MAPKAPK2, HSP27, and ATF2 phosphorylation. *PLoS ONE* 11(2):e0149486. <https://doi.org/10.1371/journal.pone.0149486>
 159. Wang Y, Kellner J, Liu L, Zhou D (2011) Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion. *Stem Cells Dev* 20(7):1143–1152. <https://doi.org/10.1089/scd.2010.0413>
 160. Wang J, Lu X, Sakk V, Klein CA, Rudolph KL (2014) Senescence and apoptosis block hematopoietic activation of quiescent hematopoietic stem cells with short telomeres. *Blood* 124(22):3237–3240. <https://doi.org/10.1182/blood-2014-04-568055>
 161. Jiang Y, Xu Z, Ma N, Yin L, Hao C, Li J (2021) Effects of signaling pathway inhibitors on hematopoietic stem cells. *Mol Med Rep*. <https://doi.org/10.3892/mmr.2020.11647>
 162. Sorimachi Y, Karigane D, Ootomo Y, Kobayashi H, Morikawa T, Otsu K et al (2021) p38 α plays differential roles in hematopoietic stem cell activity dependent on aging contexts. *J Biol Chem* 296:100563. <https://doi.org/10.1016/j.jbc.2021.100563>
 163. Segalés J, Perdiguero E, Muñoz-Cánoves P (2015) Epigenetic control of adult skeletal muscle stem cell functions. *Febs j* 282(9):1571–1588. <https://doi.org/10.1111/febs.13065>
 164. Borodkina A, Shatrova A, Abushik P, Nikolsky N, Burova E (2014) Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells. *Aging (Albany NY)* 6(6):481–495. <https://doi.org/10.18632/aging.100673>
 165. Budgude P, Kale V, Vaidya A (2021) Pharmacological inhibition of p38 MAPK rejuvenates bone marrow derived-mesenchymal stromal cells and boosts their hematopoietic stem cell-supportive ability. *Stem Cell Rev Rep* 17(6):2210–2222. <https://doi.org/10.1007/s12015-021-10240-9>
 166. Wang Y, Hekimi S (2015) Mitochondrial dysfunction and longevity in animals: untangling the knot. *Science* 350(6265):1204–1207. <https://doi.org/10.1126/science.aac4357>
 167. Prakash R, Fauzia E, Siddiqui AJ, Yadav SK, Kumari N, Shams MT et al (2022) Oxidative stress-induced autophagy compromises stem cell viability. *Stem Cells* 40(5):468–478. <https://doi.org/10.1093/stmcls/sxac018>
 168. Deng W, Chen H, Su H, Wu X, Xie Z, Wu Y et al (2020) IL6 receptor facilitates adipogenesis differentiation of human mesenchymal stem cells through activating P38 pathway. *Int J Stem Cells* 13(1):142–150. <https://doi.org/10.15283/ijsc19073>
 169. Kudaravalli S, den Hollander P, Mani SA (2022) Role of p38 MAP kinase in cancer stem cells and metastasis. *Oncogene* 41(23):3177–3185. <https://doi.org/10.1038/s41388-022-02329-3>
 170. Deng K, Liu L, Tan X, Zhang Z, Li J, Ou Y et al (2020) WIP1 promotes cancer stem cell properties by inhibiting p38 MAPK in NSCLC. *Signal Transduct Target Ther* 5(1):36. <https://doi.org/10.1038/s41392-020-0126-x>
 171. Kamiya T, Hara H, Yamada H, Imai H, Inagaki N, Adachi T (2008) Cobalt chloride decreases EC-SOD expression through intracellular ROS generation and p38-MAPK pathways in COS7 cells. *Free Radic Res* 42(11–12):949–956. <https://doi.org/10.1080/10715760802566566>
 172. Hattori S, Kamiya T, Hara H, Ninomiya M, Koketsu M, Adachi T (2016) CoCl₂ decreases EC-SOD expression through histone deacetylation in COS7 cells. *Biol Pharm Bull* 39(12):2036–2041. <https://doi.org/10.1248/bpb.b16-00551>
 173. Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai EM, Hsu YL (2014) Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. *Free Radic Biol Med* 67:159–170. <https://doi.org/10.1016/j.freeradbiomed.2013.10.004>
 174. Haynes CM, Ron D (2010) The mitochondrial UPR—protecting organelle protein homeostasis. *J Cell Sci* 123(Pt 22):3849–3855. <https://doi.org/10.1242/jcs.075119>
 175. Zhao Q, Wang J, Levichkin IV, Stasinopoulos S, Ryan MT, Hoogenraad NJ (2002) A mitochondrial specific stress response in mammalian cells. *Embo j* 21(17):4411–4419. <https://doi.org/10.1093/emboj/cdf445>
 176. Martinus RD, Garth GP, Webster TL, Cartwright P, Naylor DJ, Høj PB et al (1996) Selective induction of mitochondrial chaperones in response to loss of the mitochondrial genome. *Eur J Biochem* 240(1):98–103. <https://doi.org/10.1111/j.1432-1033.1996.0098h.x>
 177. Naresh NU, Haynes CM (2019) Signaling and regulation of the mitochondrial unfolded protein response. *Cold Spring Harb Perspect Biol*. <https://doi.org/10.1101/cshperspect.a033944>

178. Haelterman NA, Yoon WH, Sandoval H, Jaiswal M, Shulman JM, Bellen HJ (2014) A mitocentric view of Parkinson's disease. *Annu Rev Neurosci* 37:137–159. <https://doi.org/10.1146/annurev-neuro-071013-014317>
179. Münch C, Harper JW (2016) Mitochondrial unfolded protein response controls matrix pre-RNA processing and translation. *Nature* 534(7609):710–713. <https://doi.org/10.1038/nature18302>
180. Fiorese CJ, Schulz AM, Lin YF, Rosin N, Pellegrino MW, Haynes CM (2016) The transcription factor ATF5 mediates a mammalian mitochondrial UPR. *Curr Biol* 26(15):2037–2043. <https://doi.org/10.1016/j.cub.2016.06.002>
181. Wu Y, Williams EG, Dubuis S, Mottis A, Jovaisaite V, Houten SM et al (2014) Multilayered genetic and omics dissection of mitochondrial activity in a mouse reference population. *Cell* 158(6):1415–1430. <https://doi.org/10.1016/j.cell.2014.07.039>
182. Wang S, Gao K, Liu Y (2018) UPR(mt) coordinates immunity to maintain mitochondrial homeostasis and animal fitness. *Mitochondrion* 41:9–13. <https://doi.org/10.1016/j.mito.2017.11.004>
183. Yi HS, Chang JY, Shong M (2018) The mitochondrial unfolded protein response and mitohormesis: a perspective on metabolic diseases. *J Mol Endocrinol* 61(3):R91–r105. <https://doi.org/10.1530/jme-18-0005>
184. Wang CL, Ohkubo R, Mu WC, Chen W, Fan JL, Song Z et al (2023) The mitochondrial unfolded protein response regulates hippocampal neural stem cell aging. *Cell Metab* 35(6):996–1008. e7. <https://doi.org/10.1016/j.cmet.2023.04.012>
185. Berger E, Rath E, Yuan D, Waldschmitt N, Khaloian S, Allgäuer M et al (2016) Mitochondrial function controls intestinal epithelial stemness and proliferation. *Nat Commun* 7:13171. <https://doi.org/10.1038/ncomms13171>
186. Zhang Q, Wu X, Chen P, Liu L, Xin N, Tian Y et al (2018) The mitochondrial unfolded protein response is mediated cell-non-autonomously by retromer-dependent wnt signaling. *Cell* 174(4):870–83. e17. <https://doi.org/10.1016/j.cell.2018.06.029>
187. Zhang Q, Wang Z, Zhang W, Wen Q, Li X, Zhou J et al (2021) The memory of neuronal mitochondrial stress is inherited transgenerationally via elevated mitochondrial DNA levels. *Nat Cell Biol* 23(8):870–880. <https://doi.org/10.1038/s41556-021-00724-8>
188. Van Camp JK, Beckers S, Zegers D, Van Hul W (2014) Wnt signaling and the control of human stem cell fate. *Stem Cell Rev Rep* 10(2):207–229. <https://doi.org/10.1007/s12015-013-9486-8>
189. Nusse R (2008) Wnt signaling and stem cell control. *Cell Res* 18(5):523–527. <https://doi.org/10.1038/cr.2008.47>
190. Mehrotra P, Ikhapoh I, Lei P, Tseropoulos G, Zhang Y, Wang J et al (2023) Wnt/BMP mediated metabolic reprogramming preserves multipotency of neural crest-like stem cells. *Stem Cells* 41(3):287–305. <https://doi.org/10.1093/stmcls/sxad001>
191. Sharma A, Mir R, Galande S (2021) Epigenetic regulation of the Wnt/ β -catenin signaling pathway in cancer. *Front Genet* 12:681053. <https://doi.org/10.3389/fgene.2021.681053>
192. Theka I, Sottile F, Cammisa M, Bonnin S, Sanchez-Delgado M, Di Vicino U et al (2019) Wnt/ β -catenin signaling pathway safeguards epigenetic stability and homeostasis of mouse embryonic stem cells. *Sci Rep* 9(1):948. <https://doi.org/10.1038/s41598-018-37442-5>
193. Wang H, Diao D, Shi Z, Zhu X, Gao Y, Gao S et al (2016) SIRT6 controls hematopoietic stem cell homeostasis through epigenetic regulation of wnt signaling. *Cell Stem Cell* 18(4):495–507. <https://doi.org/10.1016/j.stem.2016.03.005>
194. Masuda M, Uno Y, Ohbayashi N, Ohata H, Mimata A, Kukimoto-Niino M et al (2016) TNIK inhibition abrogates colorectal cancer stemness. *Nat Commun* 7(1):12586. <https://doi.org/10.1038/ncomms12586>
195. Ross J, Busch J, Mintz E, Ng D, Stanley A, Brafman D et al (2014) A rare human syndrome provides genetic evidence that WNT signaling is required for reprogramming of fibroblasts to induced pluripotent stem cells. *Cell Rep* 9(5):1770–1780. <https://doi.org/10.1016/j.celrep.2014.10.049>
196. Kornicka K, Szlapka-Kosarzewska J, Śmieszek A, Marycz K (2019) 5-Azacytidine and resveratrol reverse senescence and ageing of adipose stem cells via modulation of mitochondrial dynamics and autophagy. *J Cell Mol Med* 23(1):237–259. <https://doi.org/10.1111/jcmm.13914>
197. Khacho M, Clark A, Svoboda DS, Azzi J, MacLaurin JG, Meghaizel C et al (2016) Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. *Cell Stem Cell* 19(2):232–247. <https://doi.org/10.1016/j.stem.2016.04.015>
198. Wu MJ, Chen YS, Kim MR, Chang CC, Gampala S, Zhang Y et al (2019) Epithelial-mesenchymal transition directs stem cell polarity via regulation of mitofusin. *Cell Metab* 29(4):993–1002. e6. <https://doi.org/10.1016/j.cmet.2018.11.004>
199. Son MJ, Kwon Y, Son MY, Seol B, Choi HS, Ryu SW et al (2015) Mitofusins deficiency elicits mitochondrial metabolic reprogramming to pluripotency. *Cell Death Differ* 22(12):1957–1969. <https://doi.org/10.1038/cdd.2015.43>
200. Kasahara A, Cipolat S, Chen Y, Dorn GW 2nd, Scorrano L (2013) Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. *Science* 342(6159):734–737. <https://doi.org/10.1126/science.1241359>
201. Deng H, Takashima S, Paul M, Guo M, Hartenstein V (2018) Mitochondrial dynamics regulates *Drosophila* intestinal stem cell differentiation. *Cell Death Discov* 4:17. <https://doi.org/10.1038/s41420-018-0083-0>
202. Bahat A, Goldman A, Zaltsman Y, Khan DH, Halperin C, Amzallag E et al (2018) MTCH2-mediated mitochondrial fusion drives exit from naïve pluripotency in embryonic stem cells. *Nat Commun* 9(1):5132. <https://doi.org/10.1038/s41467-018-07519-w>
203. Fang D, Yan S, Yu Q, Chen D, Yan SS (2016) Mfn2 is required for mitochondrial development and synapse formation in human induced pluripotent stem cells/hiPSC derived cortical neurons. *Sci Rep* 6:31462. <https://doi.org/10.1038/srep31462>
204. Luchsinger LL, de Almeida MJ, Corrigan DJ, Mumau M, Snoeck HW (2016) Mitofusin 2 maintains haematopoietic stem cells with extensive lymphoid potential. *Nature* 529(7587):528–531. <https://doi.org/10.1038/nature16500>
205. Sheffer R, Douiev L, Edvardson S, Shaag A, Tamimi K, Soiferman D et al (2016) Postnatal microcephaly and pain insensitivity due to a de novo heterozygous DNML1 mutation causing impaired mitochondrial fission and function. *Am J Med Genet A* 170(6):1603–1607. <https://doi.org/10.1002/ajmg.a.37624>
206. Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferreras C, Vellon L, Menendez JA (2012) Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. *Aging (Albany NY)* 4(6):393–401. <https://doi.org/10.18632/aging.100465>
207. Forni MF, Peloggia J, Trudeau K, Shirihai O, Kowaltowski AJ (2016) Murine mesenchymal stem cell commitment to differentiation is regulated by mitochondrial dynamics. *Stem Cells* 34(3):743–755. <https://doi.org/10.1002/stem.2248>
208. Zhou TJ, Zhang SL, He CY, Zhuang QY, Han PY, Jiang SW et al (2017) Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1. *Theranostics* 7(5):1389–1406. <https://doi.org/10.7150/thno.17647>
209. Wang L, Zhang T, Wang L, Cai Y, Zhong X, He X et al (2017) Fatty acid synthesis is critical for stem cell pluripotency via promoting mitochondrial fission. *Embo j* 36(10):1330–1347. <https://doi.org/10.15252/embj.201695417>

210. Zhong X, Cui P, Cai Y, Wang L, He X, Long P et al (2019) Mitochondrial dynamics is critical for the full pluripotency and embryonic developmental potential of pluripotent stem cells. *Cell Metab* 29(4):979–92.e4. <https://doi.org/10.1016/j.cmet.2018.11.007>
211. Ho TT, Warr MR, Adelman ER, Lansinger OM, Flach J, Verovskaya EV et al (2017) Autophagy maintains the metabolism and function of young and old stem cells. *Nature* 543(7644):205–210. <https://doi.org/10.1038/nature21388>
212. Ito K, Turcotte R, Cui J, Zimmerman SE, Pinho S, Mizoguchi T et al (2016) Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance. *Science* 354(6316):1156–1160. <https://doi.org/10.1126/science.aaf5530>
213. Koehler CL, Perkins GA, Ellisman MH, Jones DL (2017) Pink1 and Parkin regulate Drosophila intestinal stem cell proliferation during stress and aging. *J Cell Biol* 216(8):2315–2327. <https://doi.org/10.1083/jcb.201610036>
214. Chaanine AH, Kohlbrenner E, Gamb SI, Guenzel AJ, Klaus K, Fayyaz AU et al (2016) FOXO3a regulates BNIP3 and modulates mitochondrial calcium, dynamics, and function in cardiac stress. *Am J Physiol Heart Circ Physiol* 311(6):H1540–H1559. <https://doi.org/10.1152/ajpheart.00549.2016>
215. Vazquez-Martin A, Van den Haute C, Cuff S, Corominas-Faja B, Cuyàs E, Lopez-Bonet E et al (2016) Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. *Aging (Albany NY)* 8(7):1330–1352. <https://doi.org/10.18632/aging.100976>
216. Tang AH, Rando TA (2014) Induction of autophagy supports the bioenergetic demands of quiescent muscle stem cell activation. *Embo j* 33(23):2782–2797. <https://doi.org/10.15252/embj.201488278>
217. Hoppins S, Lackner L, Nunnari J (2007) The machines that divide and fuse mitochondria. *Annu Rev Biochem* 76:751–780. <https://doi.org/10.1146/annurev.biochem.76.071905.090048>
218. Friedman JR, Nunnari J (2014) Mitochondrial form and function. *Nature* 505(7483):335–343. <https://doi.org/10.1038/nature12985>
219. Hoppins S, Nunnari J (2012) Cell Biology. Mitochondrial dynamics and apoptosis—the ER connection. *Science* 337(6098):1052–1054. <https://doi.org/10.1126/science.1224709>
220. Dos Santos AF, Fazeli G, Xavier da Silva TN, Friedmann Angeli JP (2023) Ferroptosis: mechanisms and implications for cancer development and therapy response. *Trends Cell Biol* 33(12):1062–1076. <https://doi.org/10.1016/j.tcb.2023.04.005>
221. Youle RJ, van der Bliek AM (2012) Mitochondrial fission, fusion, and stress. *Science* 337(6098):1062–1065. <https://doi.org/10.1126/science.1219855>
222. Westermann B (2012) Bioenergetic role of mitochondrial fusion and fission. *Biochim Biophys Acta* 1817(10):1833–1838. <https://doi.org/10.1016/j.bbabi.2012.02.033>
223. Losón OC, Song Z, Chen H, Chan DC (2013) Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. *Mol Biol Cell* 24(5):659–667. <https://doi.org/10.1091/mbc.E12-10-0721>
224. Smirnova E, Griparic L, Shurland DL, van der Bliek AM (2001) Dynammin-related protein Drp1 is required for mitochondrial division in mammalian cells. *Mol Biol Cell* 12(8):2245–2256. <https://doi.org/10.1091/mbc.12.8.2245>
225. Niemann HB, Atreya SK, Bauer SJ, Carignan GR, Demick JE, Frost RL et al (2005) The abundances of constituents of Titan's atmosphere from the GCMS instrument on the Huygens probe. *Nature* 438(7069):779–784. <https://doi.org/10.1038/nature04122>
226. Chen H, Chan DC (2017) Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. *Cell Metab* 26(1):39–48. <https://doi.org/10.1016/j.cmet.2017.05.016>
227. Zaghi M, Longo F, Massimino L, Rubio A, Bido S, Mazzara PG et al (2023) SETD5 haploinsufficiency affects mitochondrial compartment in neural cells. *Mol Autism* 14(1):20. <https://doi.org/10.1186/s13229-023-00550-9>
228. Deng L, Yi S, Yin X, Li Y, Luan Q (2022) MFN2 knockdown promotes osteogenic differentiation of iPSC-MSCs through aerobic glycolysis mediated by the Wnt/β-catenin signaling pathway. *Stem Cell Res Ther* 13(1):162. <https://doi.org/10.1186/s13287-022-02836-w>
229. Katajisto P, Döhla J, Chaffer CL, Pentimikko N, Marjanovic N, Iqbal S et al (2015) Stem cells. Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness. *Science* 348(6232):340–343. <https://doi.org/10.1126/science.1260384>
230. Wang L, Ye X, Zhao Q, Zhou Z, Dan J, Zhu Y et al (2014) Drp1 is dispensable for mitochondria biogenesis in induction to pluripotency but required for differentiation of embryonic stem cells. *Stem Cells Dev* 23(20):2422–2434. <https://doi.org/10.1089/scd.2014.0059>
231. Todd LR, Damin MN, Gomathinayagam R, Horn SR, Means AR, Sankar U (2010) Growth factor erv1-like modulates Drp1 to preserve mitochondrial dynamics and function in mouse embryonic stem cells. *Mol Biol Cell* 21(7):1225–1236. <https://doi.org/10.1091/mbc.e09-11-0937>
232. Lemasters JJ (2005) Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. *Rejuvenation Res* 8(1):3–5. <https://doi.org/10.1089/rej.2005.8.3>
233. Khaminets A, Behl C, Dikic I (2016) Ubiquitin-dependent and independent signals in selective autophagy. *Trends Cell Biol* 26(1):6–16. <https://doi.org/10.1016/j.tcb.2015.08.010>
234. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL et al (2010) Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. *Arch Neurol* 67(6):731–738. <https://doi.org/10.1001/archneurol.2010.95>
235. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 392(6676):605–608. <https://doi.org/10.1038/33416>
236. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S et al (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* 304(5674):1158–1160. <https://doi.org/10.1126/science.1096284>
237. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ (2010) Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J Cell Biol* 191(5):933–942. <https://doi.org/10.1083/jcb.201008084>
238. Pickrell AM, Youle RJ (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron* 85(2):257–273. <https://doi.org/10.1016/j.neuron.2014.12.007>
239. Orvedahl A, Sumpter R Jr, Xiao G, Ng A, Zou Z, Tang Y et al (2011) Image-based genome-wide siRNA screen identifies selective autophagy factors. *Nature* 480(7375):113–117. <https://doi.org/10.1038/nature10546>
240. Szargel R, Shani V, Abd Elghani F, Mekies LN, Liani E, Rott R et al (2016) The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway. *Hum Mol Genet* 25(16):3476–3490. <https://doi.org/10.1093/hmg/ddw189>
241. Youle RJ, Narendra DP (2011) Mechanisms of mitophagy. *Nat Rev Mol Cell Biol* 12(1):9–14. <https://doi.org/10.1038/nrm3028>
242. Palikaras K, Lionaki E, Tavernarakis N (2018) Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. *Nat Cell Biol* 20(9):1013–1022. <https://doi.org/10.1038/s41556-018-0176-2>
243. Li Y, Zheng W, Lu Y, Zheng Y, Pan L, Wu X et al (2021) BNIP3L/NIX-mediated mitophagy: molecular mechanisms and

- implications for human disease. *Cell Death Dis* 13(1):14. <https://doi.org/10.1038/s41419-021-04469-y>
244. Chen G, Han Z, Feng D, Chen Y, Chen L, Wu H et al (2014) A regulatory signaling loop comprising the PGAM5 phosphatase and CK2 controls receptor-mediated mitophagy. *Mol Cell* 54(3):362–377. <https://doi.org/10.1016/j.molcel.2014.02.034>
 245. Strappazzon F, Nazio F, Corrado M, Cianfanelli V, Romagnoli A, Fimia GM et al (2015) AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. *Cell Death Differ* 22(3):419–432. <https://doi.org/10.1038/cdd.2014.139>
 246. Salemi S, Yousefi S, Constantinescu MA, Fey MF, Simon HU (2012) Autophagy is required for self-renewal and differentiation of adult human stem cells. *Cell Res* 22(2):432–435. <https://doi.org/10.1038/cr.2011.200>
 247. Xiang G, Yang L, Long Q, Chen K, Tang H, Wu Y et al (2017) BNIP3L-dependent mitophagy accounts for mitochondrial clearance during 3 factors-induced somatic cell reprogramming. *Autophagy* 13(9):1543–1555. <https://doi.org/10.1080/15548627.2017.1338545>
 248. Song BQ, Chi Y, Li X, Du WJ, Han ZB, Tian JJ et al (2015) Inhibition of notch signaling promotes the adipogenic differentiation of mesenchymal stem cells through autophagy activation and PTEN-PI3K/AKT/mTOR pathway. *Cell Physiol Biochem* 36(5):1991–2002. <https://doi.org/10.1159/000430167>
 249. Hou J, Han ZP, Jing YY, Yang X, Zhang SS, Sun K et al (2013) Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. *Cell Death Dis* 4(10):e844. <https://doi.org/10.1038/cddis.2013.338>
 250. Wang S, Deng Z, Ma Y, Jin J, Qi F, Li S et al (2020) The role of autophagy and mitophagy in bone metabolic disorders. *Int J Biol Sci* 16(14):2675–2691. <https://doi.org/10.7150/ijbs.46627>
 251. Naik PP, Birbrair A, Bhutia SK (2019) Mitophagy-driven metabolic switch reprograms stem cell fate. *Cell Mol Life Sci* 76(1):27–43. <https://doi.org/10.1007/s00018-018-2922-9>
 252. Ivanovska IL, Shin JW, Swift J, Discher DE (2015) Stem cell mechanobiology: diverse lessons from bone marrow. *Trends Cell Biol* 25(9):523–532. <https://doi.org/10.1016/j.tcb.2015.04.003>
 253. Marcus JM, Andrabi SA (2018) SIRT3 regulation under cellular stress: making sense of the ups and downs. *Front Neurosci* 12:799. <https://doi.org/10.3389/fnins.2018.00799>
 254. Guo Y, Jia X, Cui Y, Song Y, Wang S, Geng Y et al (2021) Sirt3-mediated mitophagy regulates AGEs-induced BMSCs senescence and senile osteoporosis. *Redox Biol* 41:101915. <https://doi.org/10.1016/j.redox.2021.101915>
 255. García-Prat L, Martínez-Vicente M, Perdiguer E, Ortet L, Rodríguez-Ubreva J, Rebollo E et al (2016) Autophagy maintains stemness by preventing senescence. *Nature* 529(7584):37–42. <https://doi.org/10.1038/nature16187>
 256. Tang J, Hu Z, Tan J, Yang S, Zeng L (2016) Parkin protects against oxygen-glucose deprivation/reperfusion insult by promoting Drp1 degradation. *Oxid Med Cell Longev* 2016:8474303. <https://doi.org/10.1155/2016/8474303>
 257. Zuo W, Zhang S, Xia CY, Guo XF, He WB, Chen NH (2014) Mitochondria autophagy is induced after hypoxic/ischemic stress in a Drp1 dependent manner: the role of inhibition of Drp1 in ischemic brain damage. *Neuropharmacology* 86:103–115. <https://doi.org/10.1016/j.neuropharm.2014.07.002>
 258. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G et al (2008) Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. *Embo j* 27(2):433–446. <https://doi.org/10.1038/sj.emboj.7601963>
 259. Kageyama Y, Hoshijima M, Seo K, Bedja D, Sysa-Shah P, Andrabi SA et al (2014) Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain. *Embo j* 33(23):2798–2813. <https://doi.org/10.15252/embj.201488658>
 260. Mizushima N, Ohsumi Y, Yoshimori T (2002) Autophagosome formation in mammalian cells. *Cell Struct Funct* 27(6):421–429. <https://doi.org/10.1247/csf.27.421>
 261. Liu D, Sun Z, Ye T, Li J, Zeng B, Zhao Q et al (2021) The mitochondrial fission factor FIS1 promotes stemness of human lung cancer stem cells via mitophagy. *FEBS Open Bio* 11(7):1997–2007. <https://doi.org/10.1002/2211-5463.13207>
 262. Hong X, Isern J, Campanario S, Perdiguero E, Ramírez-Pardo I, Segalés J et al (2022) Mitochondrial dynamics maintain muscle stem cell regenerative competence throughout adult life by regulating metabolism and mitophagy. *Cell Stem Cell* 29(9):1298–314.e10. <https://doi.org/10.1016/j.stem.2022.07.009>
 263. Lunyak VV, Rosenfeld MG (2008) Epigenetic regulation of stem cell fate. *Hum Mol Genet* 17(R1):R28–36. <https://doi.org/10.1093/hmg/ddn149>
 264. Williams EG, Wu Y, Jha P, Dubuis S, Blattmann P, Argmann CA et al (2016) Systems proteomics of liver mitochondria function. *Science* 352(6291):aad0189. <https://doi.org/10.1126/science.aad0189>
 265. Rando TA, Wyss-Coray T (2021) Asynchronous, contagious and digital aging. *Nat Aging* 1(1):29–35. <https://doi.org/10.1038/s43587-020-00015-1>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.